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ABSTRACT 
Intercepting the rising rates of non-communicable diseases is currently one of the most 
exigent public health challenges faced by all nations around the world. Prevention of these 
diseases using molecules that have dietary origin may be most attractive because of their 
safety, cost-effectiveness and feasibility of oral administration. However, the mechanism of 
action of such plant-based agents remains largely unknown. In recent years, the stress 
responsive transcription factor Nrf2, has been validated as a target for disease 
chemoprevention with several small molecules. Withania somnifera (WS) is a plant that has 
been used in Ayurveda (an ancient form of medicine in South Asia) for millennia. In the recent 
past, withanolides isolated from WS, such as Withaferin A (WA) have been demonstrated to be 
preventive and therapeutic against multiple diseases in experimental models. While scientific 
research performed on WS and WA has exploded in the past decade, much regarding the mode 
of action and molecular targets involved remain unknown. The goal of this dissertation was to 
determine if WA is an inducer of Nrf2 signaling and to explore whether the cytoprotective 
response elicited by WA resulted in prevention of liver toxicity. Here, WA has been 
characterized as a potent inducer of Nrf2 signaling that profoundly protects mice against 
acetaminophen hepatotoxicity but not against non-alcoholic fatty liver disease caused by 
methionine-choline deficient diet. Further, it was shown that WA pharmacologically induces Nrf2 
signaling in a Keap1-independent, PI3K-dependent manner. Public health significance: the 
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 v 
identification of an agent isolated from a medicinal plant abundantly used in traditional medicine, 
as a novel Nrf2 inducer provides an opportunity to expand the current repertoire of Nrf2 
inducers so that culturally-appropriate chemoprevention programs can be designed to fight the 
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1.0  INTRODUCTION 
1.1 THE GLOBAL BURDEN OF NON-COMMUNICABLE DISEASE 
1.1.1 The problem 
According to the World Health Organization (WHO), the three leading causes of death in 
the world in 2012 were attributed to Ischaemic heart disease, stroke and chronic obstructive 
pulmonary disorder (COPD). These statistics are vastly different from those in 1990, where 
highest mortalities were due to communicable disease [1]. In a study published in the New 
England Journal of Medicine (NEJM) it was shown that in the US, where the top three causes of 
death were pneumonia/influenza, tuberculosis and gastrointestinal infections in 1990 
dramatically changed to non-communicable diseases such as heart disease, cancer and non-
infectious upper respiratory tract conditions in 2010 [2]. These shifts in causes of mortality are 
partly due to heavily westernized practices adopted by people living in most parts of the world. 
Less developed nations still battle issues such as malnutrition, lack of sanitation, and 
contamination of water/ foodstuffs. In a paradigm of double-burden of disease, especially within 
urban populations in less developed nations, emerging concerns of increased lifespan, 
sedentary lifestyle, overconsumption of food, pollution and exposure to new chemical agents 
have markedly increased the risk of non-communicable disease.  It is likely that these trends will 
continue to increase in the upcoming years, challenging researchers and policymakers alike to 
seek immediate solutions (Global Action Plan for the Prevention and Control of Non-
communicable diseases 2013-2020, WHO). While discovering novel therapeutics and providing 
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adequate care to patients with non-communicable conditions is an important aspect of uprooting 
the burden completely, heavy emphasis should also be given to preventing these diseases [3].  
 
1.1.2 Cancer 
Cancer is a largely heterogeneous condition that can affect different organ systems. 
Other classifications used to describe cancer include malignant tumors and neoplasms. This is 
a disease that results in significant loss in quality of life and on a larger scale takes a huge 
financial toll on a given healthcare system. While currently, cancer is not within the top three 
causes of mortality for global statistics, this is very likely to change with lifestyle changes taking 
place in largely populated areas such as China, India, Brazil, Africa and the Middle East [4]. 
Even so, in 2012, cancer accounted for 14 million new cases and 8.2 million cancer related 
deaths globally (WHO Media Center, last accessed 6/23/2015). Similar to other developed 
nations, cancer is one of the leading causes of death in the United States, second only to heart 
disease (United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based 
Report). While deaths due to certain types of cancers (breast cancer and cervical cancer) have 
decreased as a result of early detection, vaccination against HBV/ HPV [5] and better treatment 
strategies, several types of cancers still continue have extremely low 5-year survival rates. In 
spite of major breakthroughs made in the field of cancer drug discovery, researchers and 
physicians struggle to manipulate the complex biology of cancer with the current therapeutics 
available.  
Interestingly, research has shown that causes of cancer are largely preventable [6],[7]. 
While age alone is a large risk factor for developing cancer, there are several other modifiable 
factors that account for its initiation. In addition to vaccination against viral infections and 
smoking cessation, diet has been a long standing aspect of cancer where consumption of 
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certain types of food has been directly associated with a positive cancer outcome [8],[9]. 
Consumption of fruits and vegetables have been fundamentally linked to reduction in cancer risk 
while the consumption of diets high in fat may contribute to carcinogenesis or worsening of the 
phenotype [10]. Research is still unraveling the mechanisms by which certain phytochemicals 
present in fruits and vegetables can inhibit or reverse the process of carcinogenesis. It is 
apparent that targeting specific molecular pathways by these naturally-occurring, dietary agents 
is ultimately what gives rise the protective or therapeutic phenotype. 
1.1.3 The process of carcinogenesis 
The discovery of carcinogenesis dates back to 1567, when Paracelsus observed that 
European miners who were exposed to soot exhibited symptoms of wasting. This was 
corroborated by multiple other reports of disease incidence within groups of people working in 
environments that possibly exposed them to certain chemicals. The notion of carcinogenesis 
was first experimentally verified in 1915 by Japanese scientists, Yamagiwa and Ichikawa where 
application of coal tar to rabbit ears generated squamous cell tumors [11]. Since then, the field 
of chemical carcinogenesis has taken off with numerous chemicals being identified as having 
carcinogenicity. The strong causative link between aflatoxin and hepatocellular carcinoma was 
established in the 1960s in rats [12;13]. Similarly the causality between multiple chemicals and 
tumorigenesis as a result of exposure to them has been shown. A few examples among 
hundreds of others include the link between cigarette smoke and lung cancer [14] as well 
between steroidal estrogen and breast cancer [15]. One of the biggest challenges in studying 
any aspects of carcinogenesis is that it usually takes a very long time. While models of 
carcinogenesis (mice that are prone to certain types of cancers and techniques such as tumor 
xenografting) and the use of biomarkers of cancer may mitigate this problem to some degree, 
the study of tumor incidence in wild-type animals or healthy human beings can be incredibly 
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challenging unless they are predisposed to developing neoplasms. However, this lengthy nature 
of the carcinogenic process also provides ample opportunities for preventive interventions. This 
idea is demonstrated in Figure 1.1. 
 
 
Figure 1-1. The progression of cancer from a normal cell to invasive carcinoma 
(Umar et al. Nature Reviews Cancer 2012) [16]. The lengthy nature of the carcinogenesis 
process can be exploited and utilized for cancer prevention and control interventions. 
Permission to reproduce image obtained via Copyright Clearance Center, Rightslink®.  
 
Cancer is essentially the end result of the malfunctioning of a combination of inherent 
molecular networks. A normal cell is equipped with multiple defense mechanisms to protect 
itself against exogenous and endogenous insults that can cause DNA mutations.  Thus, DNA 
damage repair, removal of misfolded proteins and fighting against inflammatory injury has been 
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identified as machinery imperative to a healthy cell [17]. When this “first-line” of defense is 
absent or impaired, a normal cell is more prone to environmental stress that can ultimately lead 
to its transition into a cancerous state. In addition to the aforementioned defenses, 
cytoprotection is also provided by the effective elimination of carcinogens and other xenobiotics. 
As illustrated in figure 1.2, toxins that enter the body are metabolized in the liver and other 
organs and the purpose of the biotransformational structural modifications is to allow for higher 
water solubility for enhanced urinary excretion.  
 




Figure 1-2. Biotransformation of xenobiotics 
 
Multiple enzymes catalyze phase I reactions including cytochrome P450. These 
enzymes are expressed in a variety of locations within the cell, including the cytosol, 
mitochondria and microsomes depending on their respective catalytic function. There are 
instances where the product of the phase I reaction ends up being more reactive than the 
original toxin itself, given its highly unstable chemical nature. Acetaminophen (APAP), which is 
discussed in depth in a chapter 2 is converted into its reactive intermediate N-acetyl-p-
benzoquinone imine (NAPQI) by CYP2E1 which is what ultimately forms DNA adducts to cause 
hepatocyte necrosis. Therefore, a robust Phase II system is imperative to the effective and rapid 
biotransformation of toxic agents.  
The phase II biotransformation step greatly increases the hydrophilicity of the 
intermediate byproduct. It also requires very specific co-factors that act as substrates for the 
chemical reaction. Some of them are listed here. 1) glucoronidation (UDP-GA) 2) sulfation 








5. Amino acid conjugation 
6. Glutathione conjugation 
Phase III  
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(PAPS) 3) acetylation (acetyl CoA) 4) methylation (s-adenosylmethionine) 5) glutathione 
conjugation (Glutathione) 6) amino acid conjugation (glycine, taurine, glutamine). Dysfunction in 
overall biotransformation can have altered effects on an organism which has been observed 
with several knockout strains of CYP enzymes. CYP2E1 knockout mice were shown to be less 
sensitive to APAP that wild-type mice [18]. CYP2A1 knockout mice also seemed to develop 
normally but showed marked deficiencies in drug metabolism [19]. Although xenobiotic 
metabolism is such an important biological process to the viability of a cell/ organism, the 
reason there isn’t lethality or a more extreme phenotype associated with these CYP knockout 
animals is most likely due to the fact that there is a lot of redundancy in function. A cell and 
organism needs to be equipped with multiple mechanisms to deal with xenobiotic clearance, in 
preparation for the possibility that one pathway fails. Similarly, deficiency in enzymes involved in 
glutathione synthesis is associated with enhanced sensitivity to toxicants such as paraquat [20] 
and aflatoxin B1 [21], indicating the importance of these xenobiotic transformation pathways.  
Typically, in human beings, the process of initiation promotion to progression may take 
years if not decades, depending on the etiology of the cancer [22].   Of course, the ability of the 
individual to metabolize a given carcinogen will eventually decide the cancer outcome. 
Therefore, one could correctly predict that any successful cancer prevention intervention needs 
to include means by which these inherent cytoprotective molecular pathways are continuously 
strengthened. While enzymes that participate in xenobiotic metabolism are most abundant in 
the liver to account for the “first pass effect”, some levels are expressed in other organs too. 
Interestingly, it was shown that the tissue distribution of various CYP enzymes were vastly 
different from each other where the expression of Cyp2j9 and Cyp4x1 were found to be highest 
in the mouse brain [23]. This presumably allows for overall protection of the organism against 
exposures that occur via other routes such as inhalation or dermal exposure. Nevertheless, the 
liver functions as the organ that is primarily responsible for metabolizing drugs and toxicants.  
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1.1.4 Diseases of the liver 
The liver plays the vital role of extracting nutrients, metals, drugs, environmental toxins 
from the blood stream for catabolism, storage or excretion via bile. The portal vein transports 
blood from the stomach and intestines while the hepatic artery supplies oxygenated blood to the 
liver. While the liver has the extraordinary capacity to regenerate, several insults can cause 
permanent and irreversible damage to the liver. Chemical-induced liver injury, pathogenic 
insults (hepatitis viruses), and fatty liver are some of the most common types of injuries caused 
to the liver. Chemical-induced liver injuries may range from acute damage caused by exposure 
to drugs such as acetaminophen and ethanol to liver lesions caused by food-borne toxins (eg. 
aflatoxin). Overdose of acetaminophen over a short period of time can have the same lethal 
effect as being chronically exposed to low levels of aflatoxin. Carcinogenesis of the liver has 
been shown to be a prolonged process that takes years if not decades and typically progresses 
through multiple stages, including fibrosis and cirrhosis. Furthermore, liver cancer has been 
identified as highly preventable [24] mostly through vaccination against hepatitis B and avoiding 
fungal-contaminated foodstuffs/ alcohol [25]. The current absence of an effective vaccine 
against hepatitis C virus and rising rates in obesity-driven non-alcoholic fatty liver are likely to 
contribute towards a future epidemic in liver cancer, especially in developed nations.  
Understanding diseases of the liver provides valuable tools to understand the liver itself. 
For example, different toxicants exert damage in very different locations of the liver. The first hit 
from APAP and CCl4 is experienced by hepatocytes of zone 3 as compared to Fe overload that 
mostly damages hepatocytes in zone 1. These observations are mediated by how hepatic 
enzymes metabolize a given toxicant and where those enzymes are localized. A detailed 
description of APAP metabolism is provided in chapter 2. Furthermore, non-alcoholic fatty liver 
disease (NAFLD) provides an opportunity to study the liver under a very distinct pathological 
state [26]. Under normal conditions after the consumption of food, glucose is condensed into 
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glycogen and/or converted into free fatty acids or amino acids in the liver. However, in cases of 
fatty liver, free fatty acids accumulate followed by triglyceride synthesis. Increased insulin 
resistance, both peripheral and hepatic, leads to de novo lipogenesis. Fatty liver is also a 
condition that highlights the vital role of the liver as a metabolic organ. Furthermore, the 
identification that NAFLD can progress to hepatocellular carcinoma [27] suggests that the 
underlying etiology responsible for both pathologies are likely similar if not overlapping. Hence, 
it is important to study conditions that affect the liver in order to broaden our overall 
understanding of the organ and its function. Perhaps the notion of preventing cancer can 
broadly be applied to preventing these pathologies of the liver and vice versa given their strong 
connections at the molecular level.  
1.1.5 Chemoprevention 
In appreciation of the idea that the carcinogenic process is so prolonged, and therefore 
can be targeted for various interventions, the notion of chemoprevention was brought forward by 
Michael Sporn in 1976 [28]. To that end, chemoprevention was defined as the use of natural, 
synthetic, or biologic chemical agents to reverse, suppress, or prevent carcinogenic 
progression. Coupled with the idea that prevention of cancer (or any other disease for that 
matter) can be more beneficial than treatment, chemoprevention has become an area of great 
opportunity. Encouragingly, in human trials, tamoxifen has been shown to be effective to 
prevent breast cancer [29] and retinol has been effectively used to prevent a certain subset of 
skin cancer [30]. Even though there is a lot of space for improvement for the field of 
chemoprevention, as discussed in detail later, it is indeed appealing to observe that there are 
multiple exciting agents that are currently in trial for their chemopreventive efficacy. According to 
clinicaltrails.gov, sulforaphane for prostate cancer prevention and curcumin for colorectal cancer 
prevention are a few examples of trials that are currently ongoing. In addition to these, there are 
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several other agents that are currently being studied at the pre-clinical level that have potential 
to move forward to population-based trials.  
One of the essential features of a chemical agent that maybe utilized for 
chemoprevention is a comprehensive understanding of its biological effects. This is especially 
important because, as suggested by some researchers, the success of chemoprevention relies 
on having minimal side effects and agents that specifically target a given molecular pathway at 
a given safe dose are preferred over ones that lack specificity. However, agents that have 
multiple targets cannot be neglected. Cancer is a highly heterogeneous disease that affects 
many layers of the cellular machinery and agents with multiple targets can potentially have anti-
tumorigenic effects on several of these pathways. Furthermore, the agent needs to have high 
potency and efficacy to the end that chemopreventive regimens usually continue over a long 
period of time, and thus need to be administered less frequently as possible to give the optimal 
biological effect. In addition, being able to quantitatively measure the outcome of the 
administration of the agent, possibly by assessing how much the target molecular pathway is 
activated is important. Recognizing molecular signaling networks that can be pharmacologically 
manipulated under high specificity to mitigate the carcinogenic process is therefore a key factor 
in chemoprevention research. It would be an advantage if a candidate agent for 
chemoprevention is able to up regulate such molecular pathways in in vitro and in vivo systems. 
1.2 NRF2 
As mentioned previously, certain inherent molecular pathways and cellular machinery 
are able to protect cells and organisms against carcinogenesis, mutagenesis and other forms of 
toxicity. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that belongs to 
the Cap ‘n’ Collar basic leucine zipper transcription factor family is one such modifier that is also 
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a master regulator of the environmental stress response. Under quiescent conditions, as 
illustrated in Figure 1.4, Nrf2 is sequestered in the cytoplasm by Keap1, which facilitates its 
degradation via the formation of the proteasomal complex with Cul 3 ubiquitin ligase [31;32]. 
Under conditions of oxidative and inflammatory stresses (Figure 1.6), a conformational change 
in Keap1 allows for Nrf2 to translocate into the nucleus, heterodimerize with small Maf proteins 
and bind to the antioxidant response element (ARE) sequences present in enhancer regions of 
promoters in a battery of cytoprotective genes that encode proteins that balance redox 
homeostasis, phase-II detoxification enzymes, phase-III drug transporters and proteins that are 
involved in cellular metabolism [33],[34]. Several decades of research has also shown that Nrf2 
can be systematically induced by low concentrations of electrophilic molecules that belong to 
several classes of chemicals [35]. Interestingly, a majority of these molecules also have a 
natural and dietary origin.  
1.2.1 Discovery, function and structure 
Nrf2, a member of the cap n collar (CNC) transcription factor family that possesses 
DNA-binding activity by partnering with small Maf proteins was first cloned in the laboratories of 
Y.W. Kan (human Nrf2) [36] in 1994 and Masayuki Yamamoto (ECH, chicken Nrf2) [37] in 1995. 
Subsequently, Jaiswal’s laboratory showed that Nrf2 transcriptionally activates the expression of 
the cytoprotective enzyme, NADPH quinone oxidoreductase-1 (NQO1) through the ARE [38]. 
The generation of the Nrf2 knockout mouse by isolating the mouse Nrf2 genomic sequence and 
constructing a positive-negative selection targeting vector to disrupt the Nrf2 gene in ES cells 
marked a significant step in the field. In the same study, Yamamoto’s group also showed for the 
first time that these Nrf2-deificient mice had altered expression of ARE-regulated genes [39]. In 
addition to the impaired ARE gene battery, Nrf2-deficient mice also possessed gray-white teeth, 
later discovered to be related to altered iron metabolism [40]. In 1999, Kan et al. showed for the 
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first time that Nrf2 played a vital role in protecting mice against acute pulmonary injury induced 
by butylated hydroxytoluene (BHT) [41]. The first line of evidence to the notion that Nrf2 played 
a functional role in protecting animals against chronic disease, came from the Kensler 
laboratory where it was shown that Nrf2-deficient mice had decreased levels of cytoprotective 
enzymes that resulted in these mice being more susceptible to cancers induced by carcinogens 
such as benzo[a]pyrene [42]. Since then, a plethora of research findings have emerged that 
have characterized several different aspects of Nrf2, including the discovery of its main known 
repressor, Keap1. This is discussed in detail in a separate section.  
Human Nrf2 consists of 589 amino acids while mouse Nrf2 consists of 597 amino acids. 
It has been identified that the structure of Nrf2 allows for its interaction with several different 
binding partners. Thus far, 6 key regions (Neh1-6) of Nrf2 have been eluded to distinctive 
functions (Figure 1.3). The N-terminal region of Nrf2 contains the Neh2 domain through which 
Keap1 interacts with Nrf2. It has been shown that ETGE (strong binding) and DLG (weak 
binding) domains present in Neh2 is what interacts with the Kelch domain of Keap1 [43]. Neh4 
and Neh5 are involved in transcriptional activation while Neh1 contains the Leucine zipper and 
CNC moiety and is what directly binds to DNA. It has been demonstrated that the C-terminal 
Neh3 domain plays a role in ARE activation [44]. It was identified that there is clear distinction in 
the degree of redox sensitivity within the Nrf2 molecule where the DIDLID (amino acids 17-32) 
domain located within Neh2, which is also responsible for Nrf2’s interaction with Keap1 was 
identified as being highly redox-sensitive, while Neh6 was shown to be redox-insensitive [45]. 
The redox-insensitive property of Neh6 was further identified as being utilized to regulate Nrf2 in 
cells that had high oxidative stress. Interestingly, the half life of Nrf2 was also identified to be 
different depending on the oxidative stress status of the cell and/or whether it was degraded 
primarily through Neh2 or Neh6, where it was 10 minutes and 40 minutes respectively. Recent 
data shows that β-transducin repeats-containing proteins (β-TrCP), a novel inhibitor of Nrf2 
directly interacts with Nrf2 via its Neh6 domain [46]. The complexity of the structure of Nrf2 is 
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yet another testament of the multitude of binding partners it can have, resulting in intricate 





Figure 1-3. The structure of Nrf2 and the domains involved in the functions 
 
Providing interesting insight into how Nrf2 status ultimately dictates overall health of 
organisms, an article published in PNAS in 2015 showed that Nrf2 levels are significantly 
elevated in mole rats that naturally have a much longer lifespan than mice [47]. This observation 
was coupled with lower expression of Keap1 and β-TrCP in these animals suggesting that 
lowering mechanisms that down regulate Nrf2 activity was in fact a method by which their 
lifespans were enhanced. However, this observation doesn’t provide explanation to the notion 
that hyperactivation of Nrf2 is as deleterious as its under expression. In fact, this “dark side” of 
Nrf2 has been an important research question within the past few years, particularly with the 
identification that Nrf2 cross-talks with several pathways that have strong implications on cancer 
initiation and progression such as Notch [48],[49]  and phosphatase and tensin homolog (PTEN) 
[50],[51]. With regard to Notch, it was shown by Wakabayashi et al. that a cholangiocarcinoma-
like phenotype observed with in mice genetically overexpressing Notch Intracellular Domain 
(NICD) was partially reduced when Nrf2 was silenced in the same mice. With PTEN, co-
silencing Keap1 and PTEN resulted in bile duct carcinoma which was abrogated with the 
silencing of Nrf2 in the same mice. In addition to direct crosstalk of Nrf2 with oncogenic 
pathways, mutations in Nrf2 and Keap1 have been identified in several types of human cancers 
[52]. So far, research suggests that Nrf2 induction is an important aspect of cellular homeostasis 
and therefore needs to be balanced appropriately. Whether long-term pharmacologic activation 
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of Nrf2 would also render the same types of extreme phenotypes seen with genetic activation 
models is yet to be determined. 
. 
1.2.2 Synthesis and degradation 
Conflicting data exists about the precise nature of Nrf2 synthesis. That said, it is likely 
that multiple mechanisms contribute towards this. It was shown that Nrf2 can self-regulate itself 
via binding to ARE sequences present in the promoter region of the Nrf2 gene [53]. This is an 
important feedback mechanism to provide continuous de novo production of Nrf2, especially 
when the cell is under a type of stress. In addition to self-renewal, Nrf2 expression can also be 
driven by other transcription factors. Notch, an important player in cell renewal and repair has 
been shown to up regulate Nrf2 by the direct binding of Notch Intracellular domain (NICD) to 
RPBjk sites present in the promoter of Nrf2 [49].  Similarly, in 2005, it was shown that Nrf2 
expression is directly regulated by the binding of Aryl hydrocarbon receptor (AhR) to xenobiotic 
response element (XRE)-like sites in the Nrf2 promoter [54]. Interactions of Nrf2 with these 
molecular players along with others, results in highly sophisticated machinery that allows the 
cell to efficiently respond to exogenous and endogenous stresses.  
The degradation of Nrf2 is as tightly regulated as its expression and synthesis. Over the 
years it has been established that Keap1 forms a complex with RBX1-Cullin3-E3 Ubiquitin 
ligase that allows for Nrf2 to be degraded by the proteasome [55],[56],[32] where Nrf2 acts as 
the substrate while Keap1 acts as the adaptor to the Cul3-based E3 ligase system. This finding 
has been further corroborated by other studies where it has been identified that inhibiting the 
26s proteasome leads to rapid nuclear accumulation of Nrf2 [57]. Proteasomal subunits have 
also been identified to be direct transcriptional targets of Nrf2, suggesting that regulating the 
proteasome is an integral part of the Nrf2 signaling machinery. In a microarray analysis 
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conducted in livers of mice treated with either vehicle or 3H-1,2-dithiole-3-thione (D3T), it was 
observed that subunit components of the 19S and 26S proteasome were up regulated in wild-
type mice treated with D3T but not in Nrf2-deficient mice [58]. Nrf2 has also been shown to be 
degraded via β-TrCP-Cullin 1 [59] as well as by XBP1-Hrd1 [60]. Hrd1 regulation of Nrf2 seems 
to be unique to conditions under which the liver is cirrhotic suggesting that different pathologies 
may exhibit regulation of Nrf2 under different pathways. However, this notion has not been 
comprehensively assessed yet.       
 
 
Figure 1-4. Regulation of Nrf2 under basal conditions.  




1.2.3 Target genes of Nrf2 
Upon nuclear translocation, Nrf2 is able to bind to specific DNA sequences, known as 
AREs present in the promoter region of target genes. The specific characteristics of the ARE 
have been identified by several groups. Utilizing ChIP sequencing techniques, Malhotra et al. 
showed that Nrf2 preferentially binds to TGACTCAGC with the highest affinity [61]. 
Furthermore, DNA binding of Nrf2 is supported by heterodimerization with small maf  [37]. Since 
Jaiswal et al. published that NQO1 is a direct transcriptional target gene of Nrf2, several other 
genes have emerged as possible candidate Nrf2 targets. Many of them have well-established 
cytoprotective functions that allow for xenobiotic detoxication while others have implications in 
drug transport, cellular metabolism, immune modulation and tissue regeneration. In 1999, it was 
shown that Heme oxygenase 1 (HMOX1, HO-1) is regulated by Nrf2 [62]. However, HO-1 has 
also been shown to be regulated by other transcription factors such as NF-kB and AP-2 [63] 
suggesting that HO-1 cannot be considered to be a prototypical Nrf2 target gene. Hayes and 
Yamamoto showed that glutathione S-transferases are also regulated by Nrf2 and that these 
enzymes maybe induced via Nrf2 by synthetic chemicals, butylated hydroxyanisole and 
ethoxyquin [64]. Novel Nrf2 targets that have broader functions than the currently defined ones 
are being investigated and will provide further understanding of the role of Nrf2 in different 
cellular processes and networks.  
In a study done by comparing gene expression in livers of vehicle and D3T-treated mice 
by a microarray analysis followed by confirmation by real time PCR, several classes of signaling 
molecules were shown to be modulated, including GSH-related genes and proteasome-
associated genes [65]. In a comprehensive comparison done between genetic and 
pharmacologic amplification of Nrf2 signaling, in Keap1-deficent mice and livers of 1-(2-Cyano-
3,12,28-trioxooleana- 1,9(11)-dien-28-yl)-1H-imidazole (CDDO-Im)- treated mice respectively, it 
was shown that there was some overlap between the profiles of induced genes [33]. Some of 
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the common gene targets included glutathione-s-transferase M4 (GSTM4), NQO1, glutathione 
reductase (GSR1), Glutamate—cysteine ligase catalytic subunit (GCLC) (xenobiotic metabolism 
genes); DUSP4, MYC, IKBKG, USP2 (cell signaling genes); UDGH, PGD (carbohydrate 
metabolism genes); SLC2A1, ABCC1, ABCC4 (molecular transport genes). In another study 
that used microarray analysis to compare livers from Keap1flox/flox::AlbCre mice to controls, it was 
shown that multiple classes of genes including ones that were involved in glutathione 
metabolism as well as in phase I detoxication were upregulated [34]. In this analysis, the three 
highest fold changes were observed in glutathione peroxidase (20.9-fold), carbonyl reductase 3 
(117.9-fold) and flavin containing monooxygenase (15.4-fold). In comparison, NQO1 showed a 
5.1-fold induction and HMOX1 showed a 1.7-fold induction suggesting that Nrf2 target gene 
induction is likely not a standard measure and is dependent on multiple factors including the 
model and method of analysis used. Nevertheless, 5.1-fold induction of NQO1 is still a 
significantly large induction of mRNA expression but the activation of a large repertoire of 
multiple other genes supports the idea that cytoprotection provided by Nrf2 is in fact multi-
faceted.  
Another important consideration for the types of genes induced when Nrf2 is 
pharmacologically stimulated is, the time of response. It has been identified that transcripts of 
genes such as HMOX-1 are induced more rapidly (6 hours) as compared to NQO1 (12-24 
hours) in the rat mammary after they were orally gavaged with sulforaphane [55].  Reasons for 
this are most likely to be dependent on the nature and function of the cytoprotective enzyme 
itself. Treating mice with 100 μmol/ kg of CDDO-Im showed optimal luciferase activity at 12 
hours in NQO1-ARE-Luciferase reporter mice [66]. Thus, it is important to separately 





1.2.4 Pharmacologic inducers of Nrf2 signaling  
As mentioned previously, in several experiments conducted to show the potential 
protective role of Nrf2 against carcinogenesis and chemical toxicity, it was also shown that the 
protection rendered by small molecules such as oltipraz, tBHQ and BHT was not observed in 
Nrf2-deficient mice. This further strengthened the notion that these chemicals were in fact direct 
inducers of Nrf2 signaling. The exact mechanism by which these small molecules induce Nrf2 
was not known until the identification of key cysteine residues of Keap1 that are able to react 
with electrophilic molecules [67]. The Michael acceptor reaction between the thiol groups of 
Keap1 and electrophilic molecules is shown in Figure 1.5. Given the indispensible role of Keap1 
in Nrf2 regulation, it is evident that binding with thiol groups of Keap1 is in fact a major 
mechanism by which Nrf2 signaling is induced. However, emerging evidence also suggests that 
Keap1-independent mechanisms of Nrf2 induction by small molecules exist. These studies are 
discussed in a separate section.  
 
Figure 1-5. Michael addition reaction between thiol groups of Keap1 and electrophiles.  
Reference: Keum et al. Molecules, 2014 [68]. Open access journal.  
 
In addition to direct binding to Keap1, inducer molecules can also exhibit oxidant 
scavenging properties [69]. In particular, phenolic hydroxyl groups of inducer molecules are able 
to scavenge reactive oxygen and reactive nitrogen species, providing an additional layer of 
cytoprotection over the induction of Nrf2-regulated gene battery. Whether these bifunctional 
properties of inducers are mutually exclusive or whether they often occur simultaneously, largely 
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depends on the structure and overall biochemical nature of the inducer itself. For example, 
given the structure of sulforaphane, it can be distinguished as a molecule that is able to only 
induce cytoprotective enzymes, but in contrast, many Michael acceptors such as CDDO-Im and 
curcumin display potential to exhibit both aforementioned properties, given the presence of 
phenolic hydroxyl groups on their molecular structures [69]. Nonetheless, such broad 
classifications based on structures of inducer molecules have to be verified in multiple 
experimental models to ensure that the outcome is not assay- or cell line-dependent.  
Based on the above classification of Nrf2 inducer molecules, it poses the question 
whether the structure of the inducer ultimately governs the cellular signaling molecules it 
targets. The notion that sulforaphane covalently modifies C151 of Keap1 is well-established 
[70]. In contrast, the exact cysteine residues that CDDO-Im targets is not as clear. In a 
comprehensive comparison of several known Nrf2 inducers, Keap1-knockout and C151 mutant 
MEF were treated with varying concentrations of different inducers to determine the role that 
C151 plays in inducing Nrf2 [71]. Here it was shown that tert-Butylhydroquinone (t-BHQ), diethyl 
maleate (DEM), sulforaphane and dimethylfumerate are C151-dependent while 15d-PG-J(2), 
CDDO-Im, ebselen, nitro-oleic acid and cadmium chloride are largely C151-independent. C288 
and C273 have been shown to be other target cysteines of Keap1. In a more recent study, Nrf2 
inducing molecules were re-classified based on the cysteines of Keap1 they target [72]. Here, 
multiple inducers shown to be C151/273/288-independent. Interestingly, others have shown that 
synthetic triterpenoids target cysteines of a variety of other molecules, including PTEN. If these 
interactions subsequently alter Nrf2 induction, in the same experimental models is currently 
unknown.  
It is indeed fascinating that different inducers have preferential pathways by which they 
activate Nrf2-ARE signaling. The exact physiological nature for multiple mechanisms for 
activation is still not completely understood. However, it is likely to be dependent on first and 
foremost, the structure of the inducer. For example, if a compound possesses the desired 
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electrophilic sites that can be subjected to attack by thiol groups of Keap1, then it can be 
hypothesized that the compound is able to bind Keap1 directly, like with the case of CDDO-Im. 
But, it is necessary to understand that other key factors will also determine this interaction, such 
as the size of the inducer molecule and the exact chemical makeup. Compounds that have 
bulky side chains may not be able to bind as readily. Neighboring chemical groups to the 
electrophilic site of the compound will also likely play a role in this biochemical interaction. 
Ultimately, whether a given pharmacologic agent can bind a target cysteine of Keap1 (or any 
other molecule for that matter) are likely to be dependent on the exact position of the target thiol 
group, the neighboring amino acid groups as well as the reversibility of the reaction.  
1.2.5 Keap1-dependent regulation of Nrf2 
Kelch-like ECH associated protein 1 (Keap1) was discovered in 1999 by Yamamoto et 
al. as the first ever repressor protein of Nrf2 by evaluating transcriptional activation of different 
fusion protein constructs that corresponded to the six Neh domains of the Nrf2 [31].  Since then, 
several groups have published on key aspects of the Keap1 and Nrf2 interaction. In 2002, it was 
first identified that Keap1 dimerization is required to sequester Nrf2 in the cytoplasm [73]. The 
notion that Keap1 is an actin-bound protein was evidenced by a study by the Yamamoto group 
where it was shown that disruption of the actin cytoskeleton promoted Nrf2 nuclear entry [74]. 
From a structural standpoint, it has been shown that multiple key regions of the Keap1 protein 
are responsible for distinct functions. Evaluating the crystal structure of the human Kelch 
domain of Keap1 provided important insight into the fact that Keap1 interacted with Nrf2 through 
the Kelch domain [75]. It has also been identified that there is a unique method by which Keap1 
is regulated when the cell is under stress. Notably, de novo Nrf2 that is synthesized as response 
to cellular stress is not subject to degradation mediated by Keap1 [76]. This mechanism ensures 
that the cell can maintain high levels of Nrf2 that activates downstream cytoprotective enzymes 
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required to remove the stress without being degraded via Keap1. The physiological importance 
of Keap1 became apparent with the observation that the Keap1 knockout mouse exhibits a 
postnatal lethal phenotype [77]. These mice died postnatally, by 3 weeks of age, due to severe 
hyperkeratosis of the esophagus and forestomach. Interestingly, the lethality was rescued by 
co-silencing Nrf2 in the same mouse, suggesting that the vital role Nrf2 plays in the 
hyperkeratosis phenotype. Exact mechanistic details of this observation however, have not 
been unraveled.  
 
Figure 1-6. Regulation of Nrf2 under stress conditions.  
Image designed by Dr. Nobunao Wakabayashi. 
 
By utilizing floxing technology, mice that had disrupted Keap1 but did not possess the 
post-natal lethal phenotype were generated by the Yamamoto group in 2006 [78]. These mouse 
models are discussed in detail in chapter 2. This also led to the construction of mice that had 
site-specific Keap1 deletion where hepatocyte-specific Keap1-disrupted mice showed marked 
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protection from hepatotoxins. This was the first in vivo demonstration that genetic activation of 
Nrf2 leads to enhanced protection against xenobiotic stress. Both human and mouse Keap1 
consist of 624 amino acids. A schematic of Keap1 is illustrated in figure 1.7.  One of the unique 
features of Keap1 that makes it a good candidate for it to be the sensory molecule for 
electrophiles is its cysteine-rich nature. Mouse Keap1 possesses 25 cysteine residues while 
human Keap1 has 27. Reactivity of the cysteines are judged based on the nucleophilicity of the 
cysteine and its location as well as their neighboring residues that energetically allow for a 
biochemical reaction to occur with an electrophile. Experimentally, several cysteines have been 
identified as important for Nrf2 induction. C273, C288 (IVR domain) and C151 (BTB domain) 
have been shown to be critical for post-translational modifications of Keap1 that lead to Nrf2 





Figure 1-7. Structure of Keap1 
 
In addition to Nrf2, several other proteins have also been shown to be targeted by Keap1 
repressor activity. IKK beta, the kinase responsible for activating the inflammatory mediator, 
NFkB has been shown to directly associate with Keap1 [80]. The proposed mechanism of 
interaction is similar to that of Nrf2, via DLG and ETGE domains. A proteomic analysis revealed 
that dipeptidyl peptidase-3 (DPP3) targets Keap1 via ETGE [81]. Yeast two-hybrid screening 
revealed that prothymosin alpha (PTMA), a protein implicated for immune function as well as an 
oncoprotein was targeted by Keap1 as well [82]. In many of these cases, it can be hypothesized 
that these other molecules exhibit competitive inhibition for Keap1-Nrf2. It is also likely that the 
binding partner of Keap1 is dependent on the “stress status” of the cell where it would be 
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favorable for another partner to bind Keap1 and allow for Nrf2 to be released during cellular 
injury. Also, directly related to activating Nrf2, another protein targeted by Keap1 is 
SQSTM1/p62. A major modifier of the autophagy pathway, p62 has been shown to directly bind 
Keap1 to promote its degradation through the autophagasome [83],[84]. This interaction was 
first identified as a proteasome-independent pathway being responsible for degrading Keap1 
[32] and since then, it has been established that Keap1 and Nrf2 are degraded by very distinctly 
different mechanisms, by the autophagasome and the proteasome, respectively. One possible 
mechanism for the Keap1-p62 association is via the phosphorylation of p62 at S351 by 
mTORC1 [85]. Furthermore, SQSTM1/p62 has been shown to be a direct transcriptional target 
of Nrf2, suggesting that Nrf2 itself plays a role in the calculated degradation of Keap1[86]. 
Overall, Keap1 seems to be playing a regulatory role of a molecular switch that determines 
when and how to turn on Nrf2 activation. Of course, it would be naïve to assume that Keap1 is 
the sole regulator of Nrf2 as emerging evidence suggests that other mechanisms of Nrf2 
regulation also exist. The exact conditions under such alternative pathways become more 
dominant and whether or not these other mechanisms ultimately feed into the Keap1-Nrf2 
regulation loop is yet to be determined.  
1.2.6 Keap1-independent regulation of Nrf2 
Given the indispensible role of Nrf2 as a stress responsive transcription factor that 
protects cells against damage, it is fair to hypothesize that multiple mechanisms of regulation 
exist. This is particularly important under circumstances where Keap1, the major regulator of 
Nrf2 undergoes mutations. Recent analyses have shown that Keap1 shows high mutation rates 
in certain types of cancers. In lung carcinoma, Keap1 mis-sense mutations in H1184 and H1648 
residues result in the loss of ability to degrade Nrf2 appropriately [87]. Other mis-sense 
mutations, insertions and deletions in Keap1 have also been identified in approximately 20% of 
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non-small cell lung cancer tumors from patients [88]. Interestingly, almost all of these mutations 
were somatic, not germline mutations suggesting the possibility of Keap1 mutating due to 
environmental triggers. Keap1-independent mechanisms of Nrf2 regulation are illustrated in 
Figure 1.8. In this section, the focus of discussion is post-translational modifications by kinase 
pathways.  
 
Figure 1-8. Mechanisms of Keap1-independent regulation of Nrf2  
(Bryan et al. Biochemical Pharmacology 2013) [89]. Open access Journal.  
 
One of the earliest Keap1-independent Nrf2 regulators to be identified was protein 
kinase C (PKC) [90;91]. Here, it was shown that Nrf2 induction was completely suppressed by 
staurosporine and Ro-32-0432, selective PKC inhibitors and that PKC phosphorylated Nrf2 at 
Ser-40, triggering its nuclear translocation as a response to oxidative stress. While the authors 
suggested that this regulatory mechanism is dependent on Keap1, in that the phosphorylation of 
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Nrf2 occurs in a region that is also required for its interaction with Keap1, this was established 
experimentally only in vitro. When an in vivo analysis was performed the Ser-40 mutant 
behaved exactly the same as wild-type, making it difficult to fathom to relevance of the in vitro 
observation.  
Another interesting modulator of Nrf2 is phosphoinositide 3-kinase (PI3K), a highly 
abundant family of proteins that play a vital role in several different signal transduction cascades  
[92;93]. Its upstream involvement in a plethora of signaling pathways has made it a favored 
target to be tested for Nrf2 regulation. PI3K plays a role in phosphorylating and thereby 
activating AKT leading to the deactivation of glycogen synthase kinase 3 (GSK3) [94], now 
known to be a repressor of Nrf2 induction. In addition, the first report of a phytochemical 
activating Nrf2 through PI3K came in 2004, where it was shown that 10 μM carnosol, a 
compound present in rosemary and sage induced HO-1 expression in rat pheochromocytoma 
PC12 cells and resulted in Nrf2 nuclear translocation [95]. These outcomes were markedly 
reduced when cells were pre-treated for 15 minutes with LY294002, an inhibitor of PI3K. 
Epigallocatechin gallate (EGCG), a component present in green tea has also been shown to 
induce Nrf2 through PI3K in human mammary epithelial cells [96]. It was shown by the same 
group that capsaicin, isolated from red pepper also induces HO-1 expression in an Nrf2-
dependent fashion via PI3K in HepG2 cells [97].  
The PI3K pathway has been shown to be a major player in cellular biology that gives rise 
to extreme phenotypes when altered. Mice deficient of the p85α subunit of PI3K showed 
increased insulin sensitivity as well as hypoglycemia [98]. These mice likely did not show a 
more severe phenotype because there are other isoforms of the subunit that could compensate 
for the lack of another. As expected a subsequent publication showed that the loss of all protein 
products of Pik3r1 resulted in perinatal lethality [99]. Information from knockout mouse models 
suggest that PI3K has a prominent role in metabolism and development. However, PI3K 
signaling has also been implicated in redox homesostatis. Given Nrf2’s role in balancing redox 
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biology of the cell, this role of PI3K marks an important layer of regulation for Nrf2. 
Encouragingly, this has been evaluated experimentally as well. Peroxynitrite, a strong oxidant, 
induced HO-1 expression via PI3K-AKT-dependent Nrf2 activation [100], suggesting that 
modulating reactive oxygen species (ROS) is likely a mechanism by which PI3K-mediated Nrf2 
can be activated. In another study, it was shown that Nrf2 is induced by the stimulation of Ros-
EGFR-PI3K-AKT by hyperoxia in pulmonary epithelial cells [101].  
Another molecule that has been recently implicated in Nrf2 regulation, that also works 
upstream of PI3K is PTEN. PTEN overexpression in mice leads to a tumor suppressive, anti-
Warburg state [102]. On the other hand, PTEN knockout mice undergo early embryonic lethality 
[103] indicating that genetic inactivation of PTEN has deleterious effects on organisms. 
Furthermore, PTEN+/- ES cells showed hyperplasia and dysplasia in the prostate, skin and 
colon highlighting the important tumor suppressive role of PTEN, which was later corroborated 
by others [104]. PTEN C124R mutant Knockin mice showed severely impaired embryonic 
development and mice carrying one copy of the Pten mutant allele exhibited neoplasms in 
multiple organs [105]. In addition to the vital role of PTEN controlling tumor initiation, it also 
plays an important part in redox biology. It has been studied in depth with reference to Nrf2 in 
the recent years in genetic models (discussed in section 1.2.1) [51],[50]. PTEN has also been 
shown to directly bind Nrf2 inducing agents at reactive cysteine residues [106],[107] suggesting 
that it could act as a potential target for Keap1-independent Nrf2 induction. However, in the 
case of Guggulsterone [106], it was not shown whether this compound induces Nrf2 via PTEN, 
independent of Keap1 or whether this occurs simultaneously with Keap1 inactivation.  
p38 Mitogen activated protein kinase (p38 MAPK) is another signaling molecule that has 
been implicated in Nrf2 regulation. This pathway is of particular importance because it has been 
previously identified that p38 MAPK signaling can be activated by various exogenous and 
endogenous stimuli, including inflammatory cytokines, radiation and heat shock. It was shown 
very early that p38 MAPK regulated HO-1 gene expression via Nrf2 in MCF7 mammary 
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epithelial cells when treated with cadmium [108]. In a report published several months after, it 
was demonstrated that other MAPK proteins that are further upstream of p38, namely MEKK1, 
TAK1 and ASK1 can link chemical signals to Nrf2, thereby activating the ARE gene battery 
[109].  
Although there is solid evidence for PI3K (and other kinase modulators) acting as 
regulators of Nrf2, there is little information about the mechanism by which certain 
phytochemicals are able to activate these kinase pathways. With Keap1, the cysteine sensory 
system serves as a more straightforward mechanism by which electrophilic molecules are able 
to directly bind. However, with many of the other identified regulators, such derivations for 
kinase regulation of Nrf2 have not been completely presented thus far. Therefore, whether 
these kinases respond to ROS generated by these compounds, whether the activation of the 
kinases is a secondary effect of the dissociation of the Nrf2-Keap1 complex or whether they 
directly bind to the kinases or to an upstream effector molecule to activate these pathways is yet 
to be fully understood.  
A pathway that has recently been shown to have immense importance in regulating Nrf2 
independent of Keap1 is the GSK3-β-TrCP[110]. Coincidentally, this pathway has a well-
established negative regulatory role to play in Wnt/ β-Catenin signaling. It was shown that Nrf2 
directly binds β-TrCP via the Neh6 domain which is maintained at the “bound” state by the 
phosphorylation of specific serine residues of β-TrCP (serine 335, 338, 342, 347, 351 and 355) 
by GSK3 [46]. Interestingly, GSK3 works downstream of PI3K signaling where it has been 
shown that activation of PI3K (by phosphorylating Akt) leads to phosphorylation of GSK3, which 
is the inactive form of the kinase. In an independent study, it was shown that pharmacologic 
inhibition of GSK3 with 10 μM SB216763 resulted in increased Nrf2 expression and enhanced 
target gene induction [111]. In 2012, it was shown that the phenolic lignan, nordihydroguaiaretic 
acid (NDGA) induced Nrf2 stability independent of Keap1 [112]. It was also shown that this 
response was mediated by PI3K and GSK3 in both Keap1 wild-type and null MEF. To that end, 
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the regulation of Nrf2 via the GSK3-β-TrCP axis is starting to become an important 
consideration. However, it is still not completely understood whether there are conditions under 
which this pathway may become dominant over Keap1. As discussed by Cuadrado in a review 
published in 2015, it is likely that Keap1 is the principal regulator of Nrf2 under basal conditions 
[113]. However, under high oxidative stress where Nrf2 is essentially required for the clearance 
of the stress, a minor means of regulation may suffice, which is provided by β-TrCP. Thus, it 
could be envisioned that the switch between the differential regulatory mechanisms is the stress 
status of the cell or organism.  
 
1.3 WITHANIA SOMNIFERA (WS) AND WITHAFERIN A (WA)  
 
1.3.1 Withania somnifera (WS): an introduction 
1.3.1.1 Uses of WS in Ayurveda/ traditional medicine in South Asia   
 
WS (Ashwagandha; Indian winter cherry, Indian ginseng) is a medicinal plant that has 
been utilized in traditional medicine in many parts of South Asia for millennia. It belongs to the 
diverse Solanaceae family of flowering plants. Withania species show a particularly wide 
distribution throughout drier climates of the world. Although there are 23 known Withania 
species, only W. somnifera and W. coagulans (Rishyagandha) are believed to have medicinal 
benefits [114]. While they have several similarities, the WS plant is much more branched and 
has larger leaves compared to W. coagulans. WS is more commonly used in traditional 
medicine but some specific preparations also utilize W. coagulans. A few studies have identified 
B 
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that W. coagulans may also have important implications as a therapeutic to type II diabetes 
[115;116].   
WS roots (Figure 1.9.) are used in over 200 formulations in Ayurveda, Siddha and Unani 
medicine. Ashwagandha churna, powdered root of the WS plant is frequently used to treat a 
variety of ailments [117]. Further, it is also used with other ingredients. WS is used as the major 
component in Saraswati churna, which is a herbal powder mixture utilized to treat neurological 
conditions. Ashwagandhadhi lehyam is another preparation that includes WS, primarily utilized 
as a rejuvenation supplement, a treatment for male impotence and as an energy enhancer 
[118]. While these uses may seem highly divergent, it is likely that specific proportions and 
interactions with the other ingredients used in the preparations could result in highly differential 
outcomes. Interestingly, only the root of the plant is used for traditional medicine preparations. 
The use of WS in Ayurvedic concoctions has recently been evaluated by alternative medicine 
researchers where it has been shown that utilizing standardization, phytochemical screenings 
and testing for pathogen/heavy metal contamination can significantly improve the actions of 
Ashwagandadhi lehyam [118].  
 
 
Figure 1-9. Withania somnifera. left) plant and right) roots.  
Image of the plant was obtained at www.henriettesherbal.com. Permission obtained from 
Henriettesherbal to reproduce image of plant. Image of roots was captured at the National 
Institute of Traditional Medicine in Sri Lanka by Dushani Palliyaguru.  
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1.3.1.2 WS as a modern-day nutraceutical 
WS is currently sold in the US market as a herbal supplement in the form of dried 
powder capsules and as alcoholic extracts. According to the Dietary Health Education Act 
(DSHEA) of 1994, dietary supplements (a vitamin, a mineral, a herb, an amino acid, a 
concentrate etc.) was defined as a type of food intended to supplement the diet, but cannot be 
represented as conventional foods [119]. Ashwagandha supplements are mostly recommended 
for energy enhancement and to improve human exercise performance [120]. It is also used 
against a variety of other conditions- arthritis, anxiety, insomnia and bronchitis. The exact 
mechanism of action for mediating a seemingly unrelated list of ailments has not been proposed 
to date, perhaps due to the fact that Ashwagandha in general terms promotes homeostatic 
conditions allowing for optimal physiological well-being. This idea is endorsed by Ayurvedic 
practitioners where Ashwagandha is recognized as an adaptogen further suggesting that it may 
or may not have direct effects against disease but rather have implications in reinstating 
homeostasis and physiological stability. However, precise scientific studies that evaluate these 
phenomena are currently lacking. As a result of the exemption herbal supplements obtain from 
being tested in clinical trials before market release, there are limited reports on potency, efficacy 
and side effects of the specific preparations of Ashwagandha that are available in the US 
market. While most of the modern uses of Ashwagandha stem from its place in traditional 
medicine, the lack of accompanying research evidence makes it challenging to determine its full 
potential as a nutraceutical. In an evaluation of several different herbs used to improve athletic 
performance, it was identified that Ashwagandha root contained a high concentration of starch 
which likely affected its positive impact on exercise performance via carbohydrate 
supplementation [120]. Therefore, in the absence of careful quality control, it becomes tricky to 
determine the relevant biological effects of such nutraceuticals.  
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1.3.1.3 Potential to target cancer 
Mounting evidence from cell culture and animal studies suggest that WS possesses anti-
tumorigenic properties.  In 1967, it was first demonstrated experimentally that the root extract 
resulted in lowered cancer incidence in vivo [121]. Ever since, research interest in WS as an 
anti-tumorigenic agent has grown. This is apparent from the increase in the number of 
publications citing Withaferin A (WA; a withanolide from the WS plant) over the past decade 
from less than 5 in 2002 [122] to more than 50 in 2015. Researchers are just starting to scratch 
the surface of molecular pathways modulated by WS and its withanolides in order to counter the 
carcinogenic process. Not only has WS and its withanolides been shown to have therapeutic 
potential against cancer, some of them have also been shown to possess cancer preventive 
properties [123],[124],[125]. These studies are discussed in detail in later sections. The cancer 
fighting properties have been seen not only with root extracts, but also with leaf extracts which 
is a relatively underused part of the Ashwagandha plant [126]. In addition to directly protecting 
against carcinogenesis, WS and especially WA has been shown to be hepatoprotective  
[127],[128]. From the perspective of Ayurvedic medicine, there are several important 
implications of Ashwagandha for the treatment and prevention of cancer. As mentioned 
previously, the role of Ashwagandha in regeneration and rejuvenation can potentially be pivotal 
to improve longevity and quality of human life. Thus, this idea of overall health promotion may 
lead towards prevention of chronic disease like cancer. However, the dosage of Ashwagandha 
administered as treatment for cancer is presumably quite different to what is given as a general 
supplement that promotes good health. Careful research needs to be conducted to determine 
these parameters so that the factors pertaining to the use of Ashwagandha as a 







        Figure 1-10. Structure of WA.  
 
1.3.2 Bioactivity of Withania somnifera: Withaferin A and other withanolides 
1.3.2.1 Extraction and isolation 
Multiple methods are utilized to extract Ashwagandha from whole roots or leaves of the 
plant. Conventional methods usually involve extensive drying followed by grinding into a fine 
powder. Next, aqueous or organic solvent-based extraction procedures are performed where 
research suggests several ways in which extraction yields could be improved [129]. For 
example, microwave-assisted extraction can be optimized by modifying extraction time, 
temperature and solvent ratio. It has been identified that the major compounds isolated through 
alcoholic extraction of WS are alkaloids and withanolides [130]. Ultimately the best determinant 
of the success of the extraction or isolation methodology is how well the extract itself performs 
against a given disease process. A study showed that water extraction is just as viable as 
organic solvent extraction of Ashwagandha in affecting cancer cell progression [131]. More 
sophisticated methods such as high performance liquid chromatography (HPLC) coupled with 
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mass spectrometric quantification have allowed more extensive and consistent isolation of 
bioactives from Ashwagandha [132]. On the other hand, non-extraction based isolation methods 
are also used, albeit infrequently, especially within the realm of Ayurveda where whole plant 
parts are dried and used directly as a powder. While this method may preserve the integrity of 
the plant parts, using whole plant products increases chances of contamination with pathogens 
and heavy metals and may also reduce the potency due to the presence of chemicals other 
than the bioactive components in the plant. Conversely, elements of the plant matrix could 
enhance the bioactivity of WA. Nonetheless, given the high variability of withanolide 
concentrations in different plant parts and the existence of chemotypes of WS [133], 
standardization techniques need to be incorporated into these isolation practices. Furthermore, 
it is very important that preparations are made in accordance with guidelines published by the 
World Health Organization to minimize pathogens, aflatoxins, pesticide residues and heavy 
metals [132]. 
1.3.2.2 Pharmacology 
Characterization studies of WS have identified that the bioactive compounds present in 
the root, leaf and stem extract includes alkaloids and steroidal lactones. The bioactive 
compounds of WS have been further identified as withanolides, a type of steroidal lactone. So 
far, 12 alkaloids, 35 withanolides and several other sitoindosides (a withanolide containing a 
glucose molecule at carbon 27) have been identified [134;135] suggesting the diverse chemical 
makeup of the plant. Studies have shown that there is differential distribution of withanolides in 
different parts of the WS plant where WA is most abundant in the leaves as opposed to12-
deoxywithastramonolide and Withanolide A which is more profuse in the plant root [136]. In an 
in vitro model system that closely mimicked cellular absorption using Madin-Darby canine 
kidney cells, WA had much lower absorption compared to other withanolides [137]. WA has also 
been demonstrated to have higher bioavailability compared to Withanolide A when WS root 
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extract was administered to Swiss Albino female mice orally [132]. The half-life of withanolides 
was evaluated in the same study where t1/2 of WA was shown to be approximately 60 minutes 
whereas Withanolide A had a shorter t1/2 of 45 minutes [132]. Given this rapid half-life, it may be 
worth considering twice daily (BID) or three times daily (TID) of WS in dosing regimens. While 
withanolides as a whole possess several properties that could potentially be utilized against a 
variety of diseases, the majority of research work that has been conducted on withanolides 
involves WA. This in part, is due to the notion that WA is the most potent withanolide identified 
thus far from the Ashwagandha plant and was one of the first withanolides to ever be isolated 
[138-140]. The structure of WA is shown in Figure 1.10. 
The pathways for the metabolism and biotransformation of the withanolides of WS are 
poorly understood. In vitro microbial transformation of WA to 14 alpha-hydroxywithaferin A has 
been shown [141]. Given the structure of WA, it is likely that it undergoes hydrolysis (by epoxide 
hydrolase) and other reduction/oxidation reactions followed by conjugation to glutathione, 
glucuronides or sulfates. However, experimental evidence to support this claim is limited and is 
therefore an area that needs to be considered especially when studying the pharmacokinetics of 
withanolides.  
Reports of major side effects of Ashwagandha are relatively scarce making it an 
attractive agent for cancer chemoprevention in humans. To assess acute toxicity, Wistar rats 
were administered a very large dose of 2000 mg/kg WS root extract for 14 days where no 
mortality or signs of toxicity were observed [142]. However, in another study where Sprague-
Dawley rats were fed WS (dose not noted) for 14 days changes in liver and kidney 
histopathology was observed [143]. Understandably, purified withanolides have been 
associated with some minor side effects, likely due to the fact that biological effects are 
enhanced with a purified compound as compared to a crude plant extract. Administering 16 
mg/kg WA intraperitoneally for 30 days to C57BL/6J mice resulted in loss of body weight and 
changes in serum enzymes [144]. Some sedation, ptosis and ataxia were observed in Sprague-
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Dawley rats 15-20 minutes of administering a herbal concoction that contained WS at a large 
dose of 1-2 g/kg body weight [145]. From a structural standpoint, it has been hypothesized that 
observed cytotoxicity of WA against cancer cells is attributable to its epoxide group [138]. 
Further research is required to determine if the aforementioned toxic side effects can be 
alleviated by using structural analogs that have the epoxide group or any other potentially 
important chemical group modified. These studies suggest that an in vivo safe dosage range is 
available for WS but need to be established in pre-clinical studies using appropriate models.  
1.3.2.3 Structures and mechanisms of action  
Novel withanolides are still being identified by researchers [146],[147]. As mentioned 
previously, extensive work has been performed with WA where several of its structural 
properties have been identified. The cysteine-reactive nature of the α,β- unsaturated carbonyl 
group of WA is well-established [148]. WA has further been shown to directly bind to key 
cysteine residues of proteins such as Vimentin  [149], GFAP [150], IKKβ [151] and β-Tubulin 
[139]. WA has also been shown to modulate important cellular signaling processes such as 
autophagy [152], proteasomal degradation [153],[154] and the heat shock response [155]. 
Whether modulation of these processes originates from direct binding has not been elucidated. 
A study that evaluated the heat shock inducing activity of WA and several structural analogs 
showed that undesired cytotoxicity from WA could be minimized while enhancing cytoprotective 
activity by modifying WA structurally [156]. This study also suggested that there are key 
chemical moieties of the WA molecule that might be responsible for specific biological activities.  
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1.3.3 Cancer pathways modulated by Withania somnifera and its withanolides  
1.3.3.1 Cell survival/ apoptosis 
Most discussions on anti-tumorigenic properties of WS pertain to its ability to activate 
apoptotic pathways in cancer cells.  Even within the realm of cancer chemoprevention, cell 
survival and the activation of pro-apoptotic pathways holds important implications where 
successful reversal of the carcinogenesis process essentially requires the early clearance or 
destruction of impaired cells. Several currently known chemopreventive agents such as the 
isothiocyanate, sulforaphane [157] and the triterpenoid, CDDO-Im [158] exhibit this property. A 
plethora of in vitro evidence exists about the induction of apoptosis by WS [159], WA [160],[161] 
as well as other withanolides [162]. Some of the earliest hints of tumor suppression by WS 
came from a study that evaluated the potential of leaf extract to inhibit tumor formation in nude 
mice subcutaneously injected with fibrosarcoma HT1080 cells [163]. It was observed that 
treating mice with the leaf extract (0.3 mL of 24 μg/mL extract in cell growth medium, s.c.) 
resulted in reduced tumor size and was in part mediated via upregulation of p53. Interestingly, 
the authors of the paper used NMR to identify the component responsible for this action to be 
withanone. Induction of apoptosis by WA has been noted in some in vivo models where 
treatment with 4 mg/kg WA, i.p. 5 times for 2 weeks markedly reduced MDA-MB-231 tumor 
weights in nude mice as well as increased apoptosis compared to tumors in control mice [164].  
While the exact mechanisms for induction of apoptosis by WS and its withanolides are 
yet to be established, data from several publications suggest that enhanced expression of pro-
apoptotic genes as well as the suppression of proliferative pathways are possible targets. In a 
study conducted on a xenograft mouse model of cervical cancer, it was shown that 8 mg/kg WA, 
i.p. treatment for 6 weeks resulted in 70% reduction in tumor volume compared to controls as 
well as heightened expression of p53 and lowered expression of pro-caspase 3/ Bcl2 [165]. The 
ability of WA to downregulate oncogenic proteins that have anti-apoptotic function such as Bcl2 
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has been reported by others as well [166],[167]. Whether this phenomena occurs in vivo within 
the tumor micro-environment to the extent that WA can selectively slow the growth of tumor 
cells via the aforementioned mechanisms while stabilizing the apoptotic function of normal cells 
has not been clearly determined. Ultimately, to utilize WS as a chemopreventive agent, the 
pharmacological conditions under which normal cells will survive while pre-cancerous/ 
cancerous cells will undergo death need to be assessed. Selective killing of cancer cells by WA 
is an idea that has been put forward by many. By comparing cell lines that are cancerous and 
non-cancerous, WA has been shown to be cytotoxic to only cancerous cell lines [168]. A point to 
note is that, these cell lines have inherent differences that can result in differential drug uptake, 
retention and toxicity. Therefore, mechanistic explorations of how tumor cells vs. non-tumor 
cells respond to WS and its withanolides require further investigation. 
1.3.3.2 Angiogenesis 
It is widely accepted that angiogenesis is a vital process exploited by tumors to facilitate 
their own growth. In addition to tumor masses, early stage carcinogenic events may also utilize 
angiogenesis suggesting that it could be attenuated in a cancer preventive context. 
Angiogenesis has been categorized as a marker of cancer progression given the differences 
that occur in new blood vessel formation during early and late stages of carcinogenesis [169]. 
The role of WS and its withanolides on angiogenesis has been studied. The first report related 
to anti-angiogenic effect was published in 2004, where WA was shown to be a potent inhibitor of 
angiogenesis both in vitro and in vivo [170]. In another study, WS was shown to inhibit 
angiogenesis in a VEGF-induced neovascularization model in vivo [171]. An in silico study along 
with molecular docking analyses corroborated the mechanism of this finding by showing that 
WA may directly bind to VEGF and thereby hamper angiogenesis [172]. Further in vitro and in 
vivo experimentation is required to validate the physiological relevance of this finding.  
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1.3.3.3 Stress response  
In recent years, the role of stress response pathways in cancer chemoprevention has 
been closely evaluated [173]. WS and some of its withanolides have been shown to be 
mediators of the heat shock response. The heat shock response is essential to cellular 
homeostasis given its function in facilitating the degradation of misfolded proteins. 
Transcriptional regulation of multiple classes of genes by Heat shock transcription factor 1 
(HSF1) is considered to be an important regulatory step of this mechanism. WA has been 
shown to bind HSP90 to inhibit its chaperone activity through an ATP-dependent mechanism in 
pancreatic cancer cells [155].This has been proposed to be one of the mechanisms by which 
WA exerts its anti-tumorigenic activity. A multiple compound screening study that utilized heat 
shock response induction as an endpoint identified WA as one of the potent mediators of the 
heat shock response wherein 1-4 μM WA was shown to be thiol-reactive and also shown to 
induce protein expression of HSP72 and 27 [148]. In a subsequent analysis, Wijeratne et al. 
[156] demonstrated that modulation of heat shock inducing activity of WA is feasible by 
structural modifications. It is important to point out that the effect of leaf or root extracts of WS 
on heat shock response has not been determined.  
In addition to the heat shock response, several other stress response pathways have 
also been shown to be affected by WS and some of its withanolides. Several reports note that 
WA is a strong inducer of oxidative stress, mediated primarily via the generation of reactive 
oxygen species [174],[175]. Interestingly, a report by Kaur et al. [176] suggested that WS extract 
did not provide any protection against oxidative damage caused by high glucose and hydrogen 
peroxide in human cancer cells, possibly suggesting that the pro-oxidant characteristics of WA 
would not render useful in protecting against oxidative damage. The exact percentages of 
withanolides in this leaf extract were not revealed, making it difficult to understand the exact 
mechanism underlying the observation. Furthermore, whether oxidative stress induction by WA 
is a very early molecular event that facilitates downstream cytoprotective pathways in order to 
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ultimately guard cells and organisms is also currently unknown. WS and its withanolides have 
also been shown to up regulate the expression of several phase II enzyme [177],[178] 
suggesting that other cytoprotective pathways, such as Nrf2 directly or indirectly, may be 
mediated by the action of withanolides.  
1.3.3.4 Inflammation and immune regulation 
Researchers are on the brink of identifying the pivotal roles played by inflammation and 
immune function in cancer. Reducing chronic inflammation to prevent certain types of cancers 
(e.g., hepatitis virus-induced inflammation and liver cancer) as well as utilizing immunotherapy 
as a successful treatment strategy for cancer are two key widely sought after areas of current 
cancer research. It is indeed desirable that some future chemopreventive drugs possess anti-
inflammatory properties and also exhibit the ability to induce a robust immune response against 
early stage malignancies. Whether certain compounds that activate the immune system could 
potentially be utilized to prevent cancer has not been studied in detail, perhaps due to the fact 
that hyperactivation of the immune system could lead to several undesired challenges. 
Nevertheless, controlled activation of the immune system by WS is well-documented. In fact, 
two human studies with WS have looked at immunological end points [179],[180]. These studies 
suggest that the mechanism of action is driven by lymphocyte and NK cell activation. Anti-
inflammatory properties of WA are attributable to directly targeting cysteine 179 of IKK-β leading 
to the inhibition of NF-kB activity [151]. WA has also shown COX-2 inhibitory activity in some 
experimental models [181]. The anti-inflammatory and immune effects of WS and withanolides 
warrants further investigation, especially given the role of Ashwagandha as an adaptogen in 
traditional medicine.  
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1.3.4 Cancer chemoprevention with Withania somnifera/ withanolides: Pre-clinical 
studies  
Several in vivo studies strongly suggest the chemopreventive potential of WS and its 
withanolides. While many of these studies have been conducted with WA, with the appropriate 
extrapolation experiments, the findings can be extended to WS plant extracts as well providing a 
rationale to use WS in human chemoprevention studies. A summary of these studies is 
presented in Table 1.1.  
Some of the earliest work that established the chemopreventive potential of WA was 
performed on a 7,12-Dimethylbenz[a]anthracene  (DMBA)-induced oral cancer model in Golden 
Syrian Hamsters. Oral administration of 20 mg/kg WA for 14 weeks completely prevented oral 
tumor formation in these animals [182]. In a follow-up study, Manoharan et al.  [183] showed 
that this chemopreventive capacity was dependent on a circadian pattern where hamsters 
dosed with WA at 8 AM and 12 PM showed 100% protection from oral tumor formation while 
those treated at 12 AM showed 50% incidence in oral tumors [183]. Furthermore, this 
observation was in synchrony with diurnal changes in lipid peroxidation and antioxidant enzyme 
activity. Panjamurthy et al. [184] also demonstrated that there was marked reduction of p53 and 
Bcl2 protein expression in the animals treated with WA and DMBA compared to animals treated 
with DMBA alone.  
In a study conducted with MMTV-neu mice that are predisposed to developing mammary 
carcinogenesis, it was shown that there was a 33% reduction in tumor formation in mice that 
were on a diet containing 750 mg WS root extract /kg of diet for 10 months [185]. This study is 
in fact complimentary to a more detailed study that was carried out previously using WA in the 
same mouse model where it was shown that 100 μg/mouse WA (i.p., 3 times/week for 28 
weeks) resulted in lowered macroscopic tumor weights and reduced lung metastasis compared 
to control mice [123]. WA-treated mice had reduced expression of glycolysis and TCA cycle-
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related proteins, suggesting alterations in intermediary metabolism. A follow-up study that used 
tumor samples from this model [123] showed that WA inhibited self-renewal of breast cancer 
stem cells [186]. This observation was coupled with lower ALDH1 activity, endorsing the idea 
that WA was not only able to directly inhibit the cancer process by enhancing apoptosis but was 
also able to hamper stem cell machinery during carcinogenesis. Extensive mechanistic details 
of these observations were provided by Nagalingam et al., [187] where in a mammary cancer 
xenograft model, it was shown that WA treatment resulted in retarded tumor growth; reduction in 
cell proliferation marker Ki-67, survivin, and XIAP, as well as higher numbers of TUNEL-positive 
apoptotic cells [187]. Higher protein expression of pERK, pRSK, CHOP and DR-5 was also 
observed in the WA-treated group compared to control. Interestingly, the reduction of cancer 
incidence by WA was not observed in a follow-up group that had shRNA knocked-down DR-5 
implying the indispensible role of the DR-5 pathway in prevention of mammary carcinogenesis 
by WA.  
In a recent study that assessed the efficacy of WA in preventing skin carcinogenesis, 
100% protection against tumor formation was observed [125]. Carcinogenesis prone DBA/2 
female mice were subject to tumor initiation by DMBA application for 2 weeks. Subsequently, 
tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) along with 20 μg WA was applied 
topically on the same area of mouse skin once per day, five times per week, for 14 weeks. In 
the TPA+WA group, WA was applied 30 minutes prior to TPA treatment. In addition to marked 
protection against tumorigenesis, WA also blocked carcinogen-induced up regulation of acetyl-
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In addition to direct models of cancer prevention, the effect of WA on mouse xenografts 
has been assessed. Some of these studies are summarized in Table 1.2. Treatment of 4 or 8 
mg/kg WA (i.p., daily for 28 days) resulted in inhibition of PC-3 tumor growth and inhibition of 
proteasomal chymotrypsin-like activity in male nude mice [153]. Implanting a patch that 
delivered a total dose of 4 mg/kg WA resulted in 60% inhibition of A549 lung cancer xenograft 
growth compared to sham control [188]. The fact that many of the pre-clinical chemoprevention 
studies have been carried out with WA but not with WS presents the challenge of not knowing 
how WS may perform as a chemopreventive agent altogether. Utilizing carcinogenesis models 
that are most relevant to humans and parallel testing of WS extracts and purified withanolides 


















Table 1-2. Anti-carcinogenic effects of WA in cancer xenograft models. 
 
1.3.5 WA as an inducer of Nrf2 signaling 
The first hints of withaferin A qualifying as an Nrf2 inducer comes from its structure 
(Figure 1.10). Studies have shown that the α,β-unsaturated carbonyl group of WA is thiol-
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30% reduction in 
tumor volume by WA 
[190] 
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proteins; cysteine 303 of beta tubulin [139], cysteine 328 of vimentin [149] and cysteine 294 of 
Glial fibrillary acidic protein (GFAP) [150]. Thirdly, in addition to the direct binding, WA has also 
been shown to modulate several molecular players that cross-talk with the Nrf2-Keap1 pathway, 
including Notch [191] and NF-kB [192]. Fourthly, WA has been previously shown to induce 
activity of several cytoprotective enzymes such as SOD, catalase and glutathione peroxidase  
[193] as well as NQO1 [177], which again suggests that it could be functioning through Nrf2, a 
well-known master regulator of the environmental stress response. Thus, the multiple cysteines 
of Keap1 and the multitude of molecular players involved in Nrf2 regulation could be potential 
targets for direct binding or modifications by WA that could result in the activation of Nrf2, 
leading to induction of downstream cytoprotective enzyme targets. However, direct evidence of 
Nrf2 modulation by WA and possible mechanisms of action have not been proposed thus far.  
In addition to cysteine modification, WA has also been shown to have hepatoprotective 
effects in several experimental models. Jadeja et al. showed that 40 mg/kg, i.p. WA rescues 
wild-type mice from APAP-induced liver damage where Nrf2 and NQO1 protein expression was 
heightened in mice treated with WA [127] . Due to the lack of incorporation of Nrf2-knockout 
mouse models, the precise degree to which Nrf2 mediates this response remains unknown. 
Coincidentally, the role of Nrf2 as a hepatoprotective transcription factor has been shown by 
many [34],[194]. Therefore, it is predictable that the hepatoprotective actions of WA are 









2.0  WA PROTECTS THE MOUSE LIVER AGAINST APAP INDUCED HEPATOTOXICITY 
IN AN NRF2-DEPENDENT MANNER 
2.1 INTRODUCTION 
2.1.1 The mechanism of Acetaminophen-induced hepatotoxicity 
 
In addition to carcinogens that cause cancer in humans, there are several other 
toxicants that pose deleterious threats to human life. Acetaminophen (APAP; N-acetyl-p-
aminophenol, paracetamol) is one of the most commonly used analgesics against a variety of 
ailments, ranging from headaches to osteoarthritis.  However, according to the FDA, APAP was 
also the cause of 51% of acute liver failure cases in the United States in1998-2003, either from 
accidental or intentional exposures. While APAP poses no health threats at recommended 
doses, exceeding the maximum daily dose of 4g/ day can result in liver damage in humans. 
Human APAP toxicity is typically treated with N-acetylcysteine (NAC) and is proven to be 
effective if administered within 8-15 hours of APAP exposure [195] [196]. In some cases where 
liver damage is severe and irreversible, liver transplantation may be required.  
The mechanism of APAP hepatotoxicity has been elucidated in detail. APAP is 
converted into its bioactive form NAPQI in the liver by the mediation of cytochrome P450 
enzyme CY2E1 [18]. This intermediary product is successfully metabolized in the liver by 
glutathione conjugation [197] which facilitates its urinary excretion. However, in the case where 
a high dose of APAP is ingested, consistent generation of NAPQI ultimately leads to glutathione 
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depletion followed by hepatic accumulation of NAPQI, which binds to proteins and forms 
adducts causing hepatic necrosis. Histological characterization of APAP-mediated liver damage 
is typically identified by the formation of microgranulomas, hepatic necrosis and the infiltration of 
inflammatory bodies. In alignment with CYP2E1 localization in zone 3 or the periportal region, 
APAP-mediated damage is also typically concentrated in zone 3, closer to the central vein. This 





Figure 2-1. Biotransfomation of APAP in hepatocytes.  




Figure 2-2. Typical histological appearance of control or APAP-treated wild-type mouse 
liver sections stained with H&E.  
Areas that are appear in light pink are representative of regions of hepatocyte death as a result 
of APAP. Images by Dushani Palliyaguru. 
 
While APAP alone can cause significant damage to the liver, hepatotoxicity due to APAP 
is exacerbated by co-exposure to other stimuli. Alcohol has been shown to worsen APAP 
hepatotoxicity [199] where the LD50 of APAP was significantly reduced in the group of mice that 
were pre-treated with 10% alcohol in their water supply for 3 weeks compared to the control 
group. Contradicting observations have been reported in other models with regard to alcohol 
and APAP exposure where pre-treatment of Sprague-Dawley rats with 6 g/kg ethanol orally 6 
hours prior to APAP (0.5 g/kg, i.p.) essentially prevents hepatotoxicity [200].  This observation 
has been attributed to ethanol directly inhibiting the biotranformation of APAP. Acute liver injury 
is a side effect of many other drugs and medications, thus multiple other agents have been 
associated with heightened liver damage when coupled with APAP overdose. Patient cases of 
hepatitis B, C and HIV infection exacerbating APAP toxicity has also been reported [201]. These 
factors are likely to be related to compromised liver function caused by viral infection. Starvation 
status is also an important determinant of the degree of APAP hepatotoxicity as starvation has 
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been observed to induce hepatic CYP2E1, similar to long-term alcohol exposure [202]. 
Furthermore, starvation status has been shown to potentiate the effects of APAP in male 
Golden Syrian hamsters possibly due to impaired elimination of reactive APAP intermediates 
[203], specifically via glutathione conjugation.  
Given the undeniable role of Nrf2 in regulating expression of enzymes that biotransform 
toxins and toxicants, it was identified very early on that Nrf2 is in fact a key player in modulating 
APAP hepatotoxicity. Nrf2-knockout mice have been shown to be more sensitive [194]  to 
APAP-induced damage compared to their wild-type counterparts whereas hepatocytes specific 
Keap1flox/flox mice have been shown to be more resistant [78]. Further, many pharmacologic 
agents such as CDDO-Im, oleanolic acid and sauchinone have also been shown to have a 
protective effect against APAP presumably working through an Nrf2-dependent pathway  
[204],[205],[206]. These observations have largely lead to the understanding that Nrf2 has a 
protective role against APAP-mediated liver damage.  
APAP alone has also been shown to induce Nrf2 signaling. When CD-1 mice were 
administered 530 mg/kg APAP, high accumulation of nuclear Nrf2 was detected 0.5-2 hours 
after treatment [207]. Furthermore, induction of Nrf2 target genes such as GCLC, Glutamate-
cysteine ligase regulatory subunit (GCLM) and HO-1 has been observed with APAP treatment 
alone [204]. In addition to upregulating expression of cytoprotective enzymes in the liver, 400 
mg/kg APAP has been shown to enhance expression of not only NQO1 and HO-1 but also 
some ATP-binding cassette (ABC) transporters (P-gp, Mrp2, Mrp4) in the brain in an Nrf2-
dependent manner [208]. These results indicate that Nrf2 plays an important role in the 
biological response elicited by an organism to APAP exposure.  
Encouragingly, studies have shown that WA has therapeutic potential against 
hepatotoxicants such as APAP but its preventive potential has not been evaluated yet. Mice that 
were fasted overnight and administered 200 mg/kg APAP (i.p.) followed by 40 mg/kg WA (i.p., 1 
hour after APAP for 3 hours) showed lower serum alanine aminotransferase (ALT) compared to 
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control animals [127] . The authors also showed that WA-treated animals showed higher 
expression of Nrf2, NQO1 and GCLC coupled with lower expression of pro-inflammatory 
cytokines such as IL-6 and TNF-α. While the enhancement of Nrf2-ARE signaling was 
presented as a putative mechanism, the exact involvement of Nrf2 was not evaluated in this 
study.  
In addition to having major public health relevance to humans, APAP hepatotoxicity in 
mice provides a reliable and reproducible acute liver toxicity model that can be exploited to test 
the efficacy of pharmacologic agents to prevent liver injury. The role of Nrf2 in preventing APAP-
liver toxicity is well known, thus it is a suitable system to determine the potential preventive 
value of a novel Nrf2 inducer like WA. From a clinical stand point, therapeutically treating APAP 
hepatotoxicity may be of higher relevance, especially to human populations. However, one 
cannot ignore the value of extrapolations that can be derived from APAP hepatotoxicity as a 
disease prevention model. The direct applications of preventing APAP hepatotoxicity can be 
used to predict carcinogenesis outcomes in chemoprevention, given that the molecular 
foundations that define both processes share a lot in common. Of course, the limitations are 
such that other more directly relevant models of carcinogenesis need to be eventually 
incorporated into studies that seek to understand the chemopreventive potential of given 
agents. Nevertheless, prevention of APAP hepatotoxicity in murine models can serve as a 
reliable starting point to more broader studies in clinically relevant models of carcinogenesis.  
2.1.2 Mouse models of altered systemic or liver-specific Nrf2 signaling  
The generation of mouse models with differential expression of Nrf2 has provided 
extremely useful tools to study various aspects of Nrf2 signaling, the role of Nrf2 in metabolism 
of toxicants as well as the involvement of Nrf2 in disease. Some of these models were utilized in 
this study and are summarized in Table 2.1. 
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Nrf2 deleted in hepatocytes 
 
Systemic Nrf2-knockout mice were generated by Itoh et al. by isolating mouse Nrf2 
genomic sequences and constructing a positive-negative selection targeting vector to disrupt 
the Nrf2 gene in ES cells [39]. Keap1flox/flox mice were generated by Okawa et al. [78] by 
constructing a targeting vector where exons 4-6 of the Keap1 locus (region that encodes the 
double glycine repeat, DGR domain that is important for Keap1-Nrf2 interaction) were flanked 
with loxP sequences. Simultaneously, Keap1flox/flox::AlbCre mice that have hepatocyte-specific 
deletion of Keap1, were constructed by mating Keap1flox/flox mice with mice bearing cDNA 
encoding Cre recombinase under the Albumin promoter. In a later publication, it was shown that 
Keap1flox/flox mice have lower expression of Keap1 [210]. The authors speculated that this 
systemic knockdown of Keap1 was the result of the disruption of critical regulatory subunits for 
Keap1 transcription by the insertion of the EGFP cassette. Due to the same reason, 
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Keap1flox/flox::AlbCre mice too showed systemic silencing of Keap1. Hepatocyte-specific Nrf2-
deleted mice were generated by mating Nrf2flox/flox mice (loxP sites inserted flanking exon 5 or 
the DNA-binding domain of Nrf2 [209]) with mice bearing cDNA encoding Cre recombinase 
under the Albumin promoter. Genotyping was performed to determine both Nrf2 “floxing” and 
the presence of Cre recombinase.  
Skoko et al. showed that Nrf2-knockout mice in the C57BL6 background possess a 
congenital hepatic shunt compared to wild-type mice in the same background which altered 
their response to APAP [211]. Hence, it becomes important to phenotype Nrf2 knockout mice 
according to shunt status prior to APAP challenge. Skoko et al. also showed that there was a 
significant difference between shunted and non-shunted Nrf2 knockout mice in time under 
anesthesia when administered 100 mg/kg ketamine and 5 mg/kg xylazine intraperitoneally. 
Thus, this could be exploited as a characterization test of the shunt status of these mice. This 
finding along with other observations that assist in distinguishing between shunted and non-
shunted Nrf2 knockout mice have been summarized in Table 2.2. The shunt status of 
hepatocyte-specific Nrf2 deleted mice has not been evaluated but preliminary observations 












Table 2-2. Comparison of shunted and non-shunted Nrf2 knockout mice based on 





Non-shunted Nrf2 knockout 
 
Shunted Nrf2 knockout 
 
Liver/ body weight ratio 
 
 




Lower than age matched non-
















Less localized to zone 3 











Not responsive to APAP-
induced hepatotoxicity 
 




Sleep time = 60 minutes 
 
Sleep time > 80 minutes 
 
Parameters are based on observations made during our studies as well as published data from 
Skoko et al. Tox Sci 2014 and Beyer et al. EMBO J 2008. 
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2.2 HYPOTHESIS 
WA protects mice against APAP-induced hepatotoxicity in an Nrf2 dependent manner. 
2.3 METHODS AND MATERIALS 
Animals and husbandry 
Wild-type male C57BL/6J mice (25-33 g) were purchased from Jackson Laboratories. 
Nrf2 knockout mice have been discussed in section 2.1.2. All animals were fed a standard chow 
diet unless under noted starvation conditions with access to ad libitum water. Gavage doses 
were given in a volume of 100 μl. Intrapreritoneal doses were given in 500 μl. WA did not result 
in toxicity at any of the doses used, as evidenced by liver histology and serum ALT. For serum 
ALT measurements, blood was drawn by cardiac puncture and for histological analyses, livers 
were fixed in formalin. All experiments were performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee at University of Pittsburgh.  
In vivo WA dosing experiments 
Graded doses of WA in DMSO (DMSO, 1, 3, 7, 10 mg/kg) were administered orally to 
mice for 20 hours the dose-response experiment and 7 mg/kg WA was administered for the 
time-course experiment for 0, 6, 12, 20 and 48 hours after which mice were euthanized and 
livers were harvested. For the multiple organ experiment, 7 mg/kg WA was given orally for 20 
hours and brain, lung, liver, kidney, small intestinal epithelial lining, whole colon were extracted. 
For the multiple dosing experiment mice were gavaged with 7 mg/kg WA every other day for a 
week and sacrificed 20 hours post final dose (dosed on Monday-Wednesday-Friday and 
sacrificed on Saturday) upon which animals were euthanized and livers were harvested for 
further analysis.  
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RNA isolation and Real time PCR  
RNA from mouse organ homogenates was extracted and purified using an RNA 
extraction kit (5-PRIME). For organs that had high lipid content, Trizol (Invitrogen) was used. 
RNA integrity was confirmed by electrophoresis. Quantification of RNA concentrations was 
performed using UV spectrophotometry at 260 nm and 280 nm. Absorbance at 260/ 
Absorbance at 280 was utilized to determine the purity of RNA. 1 μg of RNA was used to 
synthesize cDNA with the qScript system (Quanta Biociences). All primers were designed using 
Primer Bank software. Primer annealing temperatures were determined by semi-quantitative 
PCR with gradient temperature. Real time PCR was performed on a 242 Bio-Rad My-IQ 
machine (Applied Biosystems) with SYBR green (Bio-Rad). PCR efficiency was determined 
using a standard curve and the Pfaffl method was used for quantifications of fold changes.  
2.4 RESULTS 
2.4.1 Phenotyping and validating the mouse models  
Anesthetizing Nrf2 knockout mice with 100 mg/kg ketamine and 5 mg/kg xylazine 
showed that non-shunted mice slept for a significantly lesser time (mean=60 min) compared to 
shunted mice (mean=90 min) (Figure 2.3). These findings were in line with Skoko et al. [211]. 
Non-shunted Nrf2-knockout mice were subsequently utilized for APAP experiments. 
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Figure 2-3. Sleep time for anesthesia induced by 100 mg/kg ketamine and 5 mg/kg 
xylazine (i.p.) for Nrf2 knockout mice.  
Animals were placed on their back after anesthesia and time to roll over was noted. Mice were 
subsequently utilized for APAP treatments based on shunt status. 
 
Analysis of liver DNA from Nrf2flox/flox mice showed only undeleted and “floxed” Nrf2 (at 
350 bp) while Nrf2flox/flox::AlbCre mouse liver DNA showed two bands for both deleted and 
undeleted Nrf2 (500 bp and 350 bp respectively) (Figure 2.4, left panel). The undeleted band 
most likely corresponded to undisrupted Nrf2 coming from cells other than hepatocytes in the 
liver. Hepatocyte-specific Nrf2 deleted mice (Nrf2flox/flox::AlbCre) and Nrf2-knockout mice were 
shown to have much lesser mRNA expression of NQO1 at basal state as a result of Nrf2 
deletion  compared to wild-type and Nrf2 flox/flox controls (Figure 2.4, right panel). This data also 
suggested that wild-type and Nrf2 flox/flox mice had similar basal levels of NQO1 transcripts in the 
liver. Compared to the systemic Nrf2-knockout, hepatocyte-specific Nrf2 deleted mice showed 
higher mRNA levels of NQO1 which maybe attributable to basal NQO1 expression maintained 
by cells other than hepatocypes in the liver. Hepatic kupffer cells [212] and cholangiocytes [213] 
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have been shown to express Nrf2 and therefore may contribute to higher basal expression of 
Nrf2 target genes in Nrf2flox/flox::AlbCre mice. Collectively, this data suggested that Nrf2flox/flox mice 
were comparable to wild-type mice in terms of their hepatic Nrf2 target gene expression under 
basal conditions and that systemic Nrf2 knockout and Nrf2flox/flox::AlbCre showed impaired 
hepatic NQO1 expression compared to wild-type mice.  
 
Figure 2-4. Characterization of Nrf2flox/flox::AlbCre mice.  
Left) Cre recombinase regulated by the Albumin promoter allows for liver-specific floxing of the 
Nrf2 alleles. Bands corresponding to the presence of Cre recombinase were detected only in 
the liver and tail of Nrf2flox/flox::AlbCre mice (not shown). Right) Fold change of NQO1 transcripts 
in wild-type, Nrf2flox/flox, Nrf2-knockout and Nrf2flox/flox::AlbCre mice at basal level. Values are 
mean ± SEM (n=4). Statistical significance compared to wild-type (*p<0.05).  
2.4.2 WA protects mice against APAP hepatotoxicity in an Nrf2-dependent manner 
Pre-treating wild-type mice with 7 mg/kg WA (p.o.) substantially protected them against 
liver damage caused by 250 mg/kg (i.p.) (Figure 2.5). Liver damage was quantified and 
assessed by serum ALT and histological analyses of H & E stained liver sections for hepatocyte 
necrosis closer to the central vein. This protection was not observed in systemic Nrf2-knockout 
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mice. Nrf2-knockout mice were categorized according to shunt status by measuring the sleep 
time under ketamine/xylazine anesthesia. Furthermore, when Nrf2flox/flox and hepatocyte-specific 
Nrf2 deleted Nrf2flox/flox::AlbCre mice were subjected to the same dosing protocol, it was 
observed that Nrf2flox/flox mice were protected, much like the wild-type mice but the 
Nrf2flox/flox::AlbCre did not exhibit this protection. Comparison across genotypes of mice shows 
that Nrf2flox/flox::AlbCre mice have higher sensitivity to APAP hepatotoxicity compared to both 
wild-type and systemic Nrf2 knockout mice, probably due to the indispensible role of Nrf2 in 
protecting the liver and specifically hepatocytes against damage from hepatotoxins. The reason 
for ALT levels of wild-type mice treated with DMSO and APAP being significantly lower 
compared to Nrf2flox/flox mice treated the same may be justified by discrepancies in APAP 
solubility. APAP does not go into solution readily in saline and therefore the saline had to be 
pre-warmed , allowing for a certain degree in variability of how much APAP is actually in 
solution in each preparation. Control experiments (data not shown) showed that wild-type, Nrf2-
knockout, Nrf2flox/flox and Nrf2flox/flox::AlbCre mice did not show statistically different changes in 
serum ALT when treated with 7 mg/kg WA followed by saline control. Overall, this data 
collectively suggested that WA provides profound protection that is directly mediated by Nrf2, 
against liver damage caused by APAP and therefore could have important implications in the 
prevention of toxicity in organisms.  
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Figure 2-5. WA-mediated protection against APAP hepatotoxicity 
A) Schematic of dosing protocol. Mice were treated with either DMSO or 7 mg/kg WA (p.o.), 
followed by 22 hours of starvation before administration of 250 mg/kg APAP (i.p.) in saline for 6 
hours. B) Serum ALT for wild-type and Nrf2-knockout mice that underwent the dosing regimen 
in A. Wild-type values are n=6 ± SEM; Nrf2-deficient values are n=15 ± SEM. C) Representative 
H&E staining of livers of mice in B. D) Serum ALT for Nrf2flox/flox and Nrf2flox/flox::AlbCre mice that 
underwent the dosing regimen in A. All values are n>5 ± SEM. E) Representative H&E staining 
of livers of mice in D. Statistical significance (*) of all ALT values was determined by p<0.05 
(one-way Anova and Tukey’s multiple comparison test) * significantly lower than DMSO control; 
n.s. not significantly lower than DMSO control. Histology images are 10X magnification and are 
representative of all animals within each group.  
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2.4.3 WA induces Nrf2 target gene expression in vivo 
To further investigate the involvement of Nrf2 in WA-mediated cytoprotection, induction 
of Nrf2 target genes in the mouse liver post WA treatment was evaluated. Mice were gavaged 
with DMSO vehicle, 1, 3, 7 and 10 mg/kg WA for 20 hours to determine the dose-response of 
hepatic NQO1 transcript induction where it was observed that 7 mg/kg WA resulted in optimal 
induction (Figure 2.6A). As per previous reports, 10 mg/kg WA is not lethal or toxic to mice. 
However, a lowered induction of NQO1 was observed at this WA dose suggesting that the 
cytoprotective window for NQO1 induction by WA likely lies at less than 10 mg/kg WA. It is still 
likely that WA continues to provide other layers of protection at higher doses that maybe 
dependent or independent of Nrf2-mediated transcription of cytoprotective enzymes. In a time-
course analysis, 20 hours post-treatment of 7 mg/kg WA resulted in ~6-fold induction of liver 
NQO1 transcripts (Figure 2.6B). The dose and time windows were picked based on previous 
publications that are listed in Table 1.1 and 1.2. In an analysis of target genes other than NQO1, 
it was observed that hepatic GST3A, GSTM4 and GSR1 were all significantly up-regulated by a 
single dose of 7 mg/kg WA (Figure 2.6C) as well as by three doses of 7 mg/kg WA (q.o.d X3, 
sacrifice 20 hours after the final WA dose) (Figure 2.6D). This is an important finding that further 
validates the observations made in the APAP study given the involvement of these enzymes in 
glutathione synthesis. In an effort to determine whether Nrf2 target genes are induced in organs 
other than the liver, it was observed that WA treatment resulted in significant induction of NQO1 
and GCLC in the mouse brain, small intestinal epithelium, lung and whole colon in addition to 
the liver (Table 2.1). Interestingly, many of these organs in addition to the liver such as the lung 
and the small intestinal epithelium have important cytoprotective function given their constant 
exposure to environmental chemicals and toxicants. It was particularly interesting to see 
significant induction of brain NQO1 as a similar observation was made with CDDO-Im in a 
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previous study [66] suggesting that Nrf2 inducers can potentially be utilized to prevent and/or 
treat conditions that affect a large spectrum of organs.  
 
Figure 2-6. WA-mediated induction of cytoprotective enzyme expression 
A) Dose-response (0, 1, 3, 7, 10 mg/kg body weight) for induction of hepatic NQO1 20 hours 
after oral WA treatment of mice. B) time-course for induction of hepatic NQO1 transcripts after 
WA treatment (7 mg/kg, p.o.) of mice. C) Induction of Nrf2 target genes in livers of mice treated 
with a single dose of oral 7 mg/kg WA. Livers were extracted 20 hours after WA treatment. D) 
Induction of Nrf2 target genes in livers of mice treated with 3 doses of oral 7 mg/kg WA. Mice 
were gavaged on alternating days and livers were extracted 20 hours after the 3rd WA 
treatment. GAPDH was used as the housekeeping gene for all Real time quantitative PCR 
experiments. All values are n>5 ± SEM. Statistical significance (*P<0.05) was determined by 
Student’s t-test compared to DMSO control.  
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Table 2-3. Induction of NQO1 and GCLC transcripts in organs 20 hours post a single oral 
dose of 7 mg/kg WA in wild-type mice.  
 
Organ Fold change of NQO1  Fold change of GCLC  
Brain 2.6 ± 0.4*  3.2 ± 0.1 *  
Small intestinal epithelium 4.4 ± 0.8*  2.5 ± 1.1*  
Stomach 2.0 ± 0.2 2.2 ± 0.1 
Lung 3.3 ± 0.1*  2.6 ± 0.3 *  
Liver 3.1 ± 0.3*  2.5 ± 0.3 *  
Kidney 2.1 ± 0.2 2.2 ± 0.4   
Whole colon 4.0 ± 1.0*  3.7 ± 1.3*  
GAPDH was used as the housekeeping gene for all Real time quantitative PCR experiments. 
Values are mean ± SEM (n=5). Statistical significance (*) was determined by p<0.05 (Student’s 
t-test) compared to DMSO control. 
 
2.4.4 Hepatic NQO1 induction by WA is Nrf2-dependent 
Comparison of hepatic NQO1 transcripts in wild-type, Nrf2 knockout Nrf2flox/flox and 
Nrf2flox/flox::AlbCre  mice that were treated with 7 mg/kg WA showed that the induction observed 
in wild-type and Nrf2flox/flox was not observed in Nrf2 knockout and Nrf2flox/flox::AlbCre mice 
suggesting that NQO1 induction by WA is in fact Nrf2-dependent (Figure 2.7). Compared to the 
systemic Nrf2 knockout liver, the Nrf2flox/flox::AlbCre liver showed slightly higher induction of 
NQO1, possibly attributable to Nrf2 signaling activated in cell types other than hepatocytes. 
Nonetheless, both systemic and Nrf2flox/flox::AlbCre livers showed impaired induction of NQO1 by 
 62 
WA suggesting that Nrf2 signaling is a major contributor to the cytoprotective enzyme 




Figure 2-7. Induction of NQO1 transcripts 20 hours after WA treatment in mouse livers.  
Values are mean ± SEM (n=3). Statistical significance is from comparison to basal NQO1 level 




The role of Nrf2 in cytoprotection and organoprotection against carcinogenesis and other 
forms of toxicity is indisputable. Therefore, one of the best determinants of the physiological 
relevance of Nrf2 activity is how well an organism is protected against a given toxicant. The role 
of Nrf2 in APAP hepatotoxicity is well-researched and therefore deemed a plausible model 
system to test the potential of WA to induce cytoprotection mediated by Nrf2 signaling. Our 
results directly indicate that WA profoundly protects mice against APAP hepatotoxicity in an 
Nrf2-dependent manner. The mechanism of action is likely to involve up regulating ARE-genes 
(that play an important role in glutathione synthesis) via activating the Nrf2 signaling cascade in 
hepatocytes such that by the time NAPQI is formed, hepatocytes are already in a “primed” state 
with higher reserves of glutathione, via the upregulation of enzymes involved in glutathione 
synthesis and other cytoprotective machinery activated allowing for more rapid clearance of 
NAPQI. Whether WA can directly bind to NAPQI to expedite its clearance is not known. Perhaps 
another layer of protection could be provided through the direct inhibition of CYP2E1 by WA. 
Some research suggests that sulforaphane can directly inhibit CYP2E1 [214] while others 
suggest that no changes in CYP2E1 expression or activity results from sulforaphane but rather 
only a protection against CYP2E1-mediated toxicities is possible [215]. Whether WA is able to 
mediate expression or activity of CYP2E1 to lower rates of NAPQI formation has not been 
elucidated. It is important to keep in mind that retarding CYP2E1 could potentially lead to 
unmetabolized APAP accumulation as well as preferred glucuronidation/ sulfation of APAP. 
APAP accumulation could also have deleterious effects unless another cytochrome p450 
enzyme compensates for its absence. While APAP glucuronide and APAP sulfate are 
predominantly excreted via blood and bile, overwhelming production of these metabolites in the 
absence of CYP2E1 could also potentially have adverse effects. However, these are 
phenomena that need to be validated. Of course, Nrf2 induction occurs as a result of the 
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toxicant itself too [216]. However, within a 6 hour exposure it is unlikely that APAP was able to 
induce Nrf2 signaling given that induction of cytoprotective enzymes by Nrf2 typically requires 
12-24 hours [217].  
While NAPQI-protein adduct formation was thought to be the primary cause of hepatic 
necrosis following APAP toxicity, recent data suggests the involvement of peroxynitrite, a 
reactive nitrogen species formed by the very rapid reaction of superoxide and nitric oxide (NO) 
[218]. While NAC has been shown to scavenge peroxynitrite in addition to conjugating with 
NAPQI, it is interesting to question if WA is also able to exhibit such a property. Reactive 
oxygen species scavenging properties of Nrf2 inducers have been evidenced under different 
circumstances and well could be applied to WA as well. Another mechanism of injury related to 
APAP toxicity has been proposed within the past few years. Cytokine secretion by activated 
kupffer cells has been shown to be associated with the necrosis observed in hepatocytes after 
APAP exposure [219],[220],[221]. Several publications support the idea that macrophages play 
an important role in the clearance of accumulated NAPQI and other reactive metabolites, but it 
could also have an inflammatory effect that could potentially aggravate the liver damage. It is 
plausible that WA orchestrates an anti-inflammatory response via Nrf2 (as has been shown with 
sulforaphane [222]) to protect the liver even further.  
The idea that WA induces cytoprotective enzymes such as NQO1, GSTM4, GSR, 
GST3A and GCLC and likely contributed towards protecting mice against APAP hepatotoxicity 
was corroborated by evaluating their transcript levels post WA gavage in mouse liver. Induction 
of these enzymes by other Nrf2 inducers such as sulforaphane is well-documented [217],[223]. 
A 6-fold induction of hepatic NQO1 transcripts was observed with a single dose of 7 mg/kg WA. 
Cornblatt et al. showed that 150 μmol sulforaphane (p.o.) resulted in approximately the same 
fold change in NQO1 transcripts in the mammary gland of female Sprague-Dawley rats [217]. 
Yates et al. showed that with 10 μmol/ kg CDDO-Im (p.o.), ICR mice showed approximately 10-
fold induction of NQO1 transcripts after 6 hours [66]. Species and gender differences permitting, 
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it is still deducible that WA potently activates the prototypical battery of genes transcriptionally 
regulated by Nrf2. The possibility of GST3A being an Nrf2 target gene has been debated where 
in a recent publication it was shown that GST3A is not readily inducible by CDDO-Im [224]. The 
induction of cytoprotective enzymes after 3 doses of WA has important implications in long-term 
dosing regimens. Ultimately, utilizing WA as a chemopreventive agent will require it to be 
consumed at frequently low doses but still have significant induction of cytoprotective enzymes. 
The induction of NQO1 and GCLC in multiple organs other than the liver suggested a response 
that could be either local or systemic. High induction in the gastrointestinal tract, liver and lung 
and some parts of the brain has been observed with other Nrf2 inducers as well [66].  This is 
further suggestive of the notion that WA could have important preventive implications against a 
variety of diseases that affect multiple organs.  
Collectively, this data strongly suggested that WA protects organisms against hepatic 
injury through an Nrf2-dependent mechanism. The strong transcriptional induction of multiple 
cytoprotective genes involved in phase II biotransformation and clearance of toxicants further 
reiterated the idea that WA modulated Nrf2 signaling. Provided that many pharmacologic 
inducers of Nrf2 act as electrophiles that attack reactive cysteines of Keap1, it is interesting to 
ask the question if WA works in a similar manner. While the structure of WA and its reactivity 
with cysteines of multiple other proteins is directly supportive of this notion, it would be 








3.0  WA IS A POTENT INDUCER OF THE NRF2 SIGNALING IN VITRO: AN EVALUATION 
OF ITS MECHANISM OF ACTION  
3.1 INTRODUCTION 
3.1.1 Studying Nrf2 induction in vitro 
Mouse embryonic fibroblasts (MEF) from mice expressing varying amounts of Nrf2 are 
valuable tools to study the role of Nrf2 under different conditions. MEFs were generated as 
previously described by isolating fibroblasts from 13.5 day-old embryos of wild-type, Keap1- 
knockout, Nrf2-knockout, and Keap1 & Nrf2-double knockout mice [79]  [48] . These mouse 
models have been described in detail in Chapter 2. Under basal conditions, Nrf2-knockout MEF 
have lower expression [225] and activity [226] of NQO1 compared to wild-type MEF. Keap1-
knockout MEF have markedly higher transcripts of Nrf2 target genes [61] compared to wild-type 
MEF suggesting that Nrf2 signaling is in fact altered in these cells in a gene-dose dependent 
manner. Sulforaphane induces NQO1 activity in wild-type MEF but not in Nrf2-knockout and 
Keap1 & Nrf2- double knockout MEF [227]. Induction of Nrf2 signaling by sulforaphane in non-
tumorigenic human mammary epithelial MCF10A cells (isolated from a fibrocystic breast 
disease patient; spontaneous immortalization) has been shown previously [228]. Furthermore, 
WA has been tested in MCF10A cells before, primarily as a normal cell comparator for cancer 
cells [139]. Luciferase reporter systems (highlighted in a below section) can provide valuable 
information to understand cellular events that either activate or deactivate Nrf2-mediated 
transcription. Furthermore, previous reports have shown that treating mice with 4 mg/kg WA 
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resulted in peak plasma concentration of 2 μM WA [229] providing understanding of how in vivo 
doses could be extrapolated to in vitro doses.  
3.1.2 End points of Nrf2 signaling induction 
Nrf2 target gene expression 
One of the best determinants of the transcription factor activity of Nrf2 is to determine 
expression or activity of downstream target genes. mRNA and protein induction of NQO1, HO-1, 
GCLM and GSTs [217],[112],[230],[64] have been classically utilized to predict Nrf2 activation 
after 6-24 hour treatments with pharmacologic agents. The Prochaska microtiter plate bioassay 
has been used in several studies to determine NQO1 enzyme activity by Nrf2 inducing agents 
[231] and provides a reliable end point to the level of Nrf2 activity. As highlighted elsewhere in 
the dissertation, several of these downstream target genes such as HO-1 belong to multiple 
regulatory networks, hence are activated by transcription factors other than Nrf2. The high 
selectivity of Nrf2 to transcriptionally activate NQO1 was demonstrated in Chapter 2 where Nrf2-
knockout mice showed significantly lower levels of hepatic NQO1 transcripts under basal 
conditions compared to wild-type mice (Figure 2.4). Coupled with observations from previous 
publications that the enhancer region of the NQO1 promoter possess Nrf2 binding ARE sites 
[38],[232], heightened NQO1 expression serves as a reliable marker of Nrf2 induction and 
activity.  
Nrf2 nuclear translocation 
Nuclear migration of Nrf2, which is otherwise sequestered and degraded in the cytosol 
under unstressed conditions, is an important manifestation of its activity. This has been reported 
with multiple pharmacologic agents such as sulforaphane [233], CDDO-Im [234], t-BHQ [235] 
and D3T [53]. Interestingly, Nrf2 carries a nuclear export signal in the leucine zipper region that 
is redox-insensitive [236], as well as a redox-sensitive signal in the Neh5 transactivation domain 
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[237] which presumably allows Nrf2 to self-regulate its activity under conditions of varying 
oxidative stress. Although Nrf2 nuclear migration is a rapid event that occurs typically within a 
few hours from pharmacologic agent treatment, the pharmacokinetics of the compound seems 
to play a role in how long nuclear import ultimately takes. t-BHQ (100 μM) showed induction in 
nuclear Nrf2 protein 3-4 hours post-treatment in HepG2 cells [90] whereas 20-50 nM CDDO-Im 
showed induction 6 hours post treatment in human peripheral blood mononuclear cells [238]. 
Therefore, the time course of Nrf2 nuclear import can vary and needs to be established for each 
Nrf2 inducer separately. Several techniques have been utilized in the past to demonstrate 
nuclear import of Nrf2, including the determination of Nrf2 protein expression in nuclear extracts 
by western blotting as well as by florescence microscopy [90].  
Transient and stable expression of Nrf2 reporter plasmid DNA 
Transient transfection of three types of vectors into MEF from Keap1 & Nrf2 double 
knockout mice provides an opportunity to study Nrf2 signaling under conditions of controlled 
expression of Nrf2 signaling [79]. The three vectors are 1) mouse Nrf2 expression vector, 2) 
mouse wild-type Keap1, 3) a luciferase reporter vector controlled by the ARE of NQO1 [239]. As 
a determinant of transfection efficiency, ARE sequence in the thymidine kinase promoter region 
of pRLTK (promega) was deleted to construct new normalizing vector, pRLTK- ΔARE [48]. 
Treating transfection complete cells with various pharmacologic agents allows for determination 
of the exact role played by Nrf2 and Keap1 in enhancing luciferase activity for each agent.  
MCF7 cells that were stably transfected with pTA-Nrf2-luciferase reporter vector, which 
contains 4 repeats of Nrf2 binding sites (AREs), a minimal promoter upstream of the firefly 
luciferase coding region and a G418 expression vector was obtained commercially (details 
highlighted in section 3.3). Cells were selected with neomycin and resistant clones were 
screened for t-BHQ induced luciferase activity. The clone with the highest fold induction was 
expanded and is the one that was utilized for our studies. These cells provide a complimentary 
tool to determine Nrf2 induction under various conditions.  
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3.2 HYPOTHESIS 
WA induces Nrf2 signaling in vitro, dependent or independent of Keap1 
3.3 METHODS AND MATERIALS 
Cell lines and reagents 
Mouse embryonic fibroblasts from wild-type, Nrf2-knockout, Keap1-knockout and Keap1 
& Nrf2 double-knockout mice were generated as described previously  [79]. MCF7 cells stably 
transfected with pTA-Nrf2-Luciferase reporter containing 4 repeats of Nrf2 binding sites was 
obtained from Signosis (SL-0010-NP). Luciferase activity in MCF7 cells was calculated by 
normalizing the Firefly luciferase readout to the number of cells in each sample. MCF10A cells 
were obtained from American Type Culture Collection. WA (Enzo Lifesciences, Farmingdale 
NY) was dissolved in DMSO at 20 mg/ml. CDDO-Im was a generous gift from Dr. Michael Sporn 
(Dartmouth College, NH). Sulforaphane was obtained from LKT laboratories (St Paul, MN). 
LY294002 and SB216763 (Cell Signaling, Danvers MA) were also dissolved in DMSO as per 
manufacturer recommendations.  
Experimental design 
All cells were seeded at 0.5 x 106 cells/well in a 6-well dish on the day prior to the 
experiment unless otherwise noted. For WA dose-response experiments, cells were treated with 
either DMSO control or 0.1, 0.3, 0.7 or 1 μM WA and RNA isolated 20 hours later. CDDO-Im 
and sulforaphane (at noted concentrations) were utilized as positive controls for Nrf2 inducing 
agents. In kinase inhibition experiments, cells were pre-treated with DMSO control/ Kinase 
inhibitor (25 μM LY294002 and 20 μM SB216763) for 1 hour followed by co-treatment with 
DMSO control/ Kinase inhibitor and DMSO control/ I μM WA for a further 8 hours. RNA isolation 
or luciferase assays were performed 20 hours later, except with kinase inhibition experiments.  
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Transfection studies 
Keap1 and Nrf2 double-deficient MEF were seeded at 0.5 x 106 cells/ well in 6-well 
plates on day 0. Plasmid DNA (5 ng pCMV Nrf2, 10 ng pRLTK- ΔARE, 100 ng pCMV NQO1-
ARE-Luc, 2.5 ng pCMV wild-type Keap1) was transfected with Lipofectamine 2000 (Invitrogen, 
Carlsbad CA) on day 1. pCMV mock vector was utilized to maintain total DNA transfected at 
400 ng. 24 hours after transfection (day 2), cells were treated with pharmacologic Nrf2 inducing 
agents (3 μM WA, 10 μM sulforaphane, 25 nM CDDO-Im). Dual Luciferase Assay (Promega, 
Madison WI) was carried out 24 hours after (day 3). Luminescence was read using a Glomax 
Multi Jr Detection system (Promega, Madison WI). 
RNA isolation and Real time PCR  
RNA from cells was extracted and purified using an RNA extraction kit (5-PRIME). RNA 
integrity was confirmed by electrophoresis. Quantification of RNA concentrations was performed 
using UV spectrophotometry at 260 nm and 280 nm. Absorbance at 260/ Absorbance at 280 
was utilized to determine the purity of RNA. 1 μg of RNA was used to synthesize cDNA with the 
qScript system (Quanta Biociences). All primers were designed using Primer Bank software. 
Primer annealing temperatures were determined by semi-quantitative PCR with gradient 
temperature. Real time PCR was performed on a 242 Bio-Rad My-IQ machine (Applied 
Biosystems) with SYBR green (Bio-Rad). PCR efficiency was determined using a standard 
curve and the Pfaffl method was used for quantifications of fold changes.  
Western blotting 
MEFs were seeded at 1.0x106 cells/ plate in 100 mm dishes and serum-starved 
overnight. For detection of nuclear Nrf2, cells were treated with DMSO control, 1 μM WA or 25 
nM CDDO-Im for either 1 or 3 hours and cells were lysed using iced cold RIPA buffer. Nuclear 
and cytosolic fractions were separated using Nuclear Extraction Kit (Abcam). For PI3K signaling 
experiments, cells were pre-treated with LY294002 for 1 hour and co-treated with LY294002/ 
WA for a further 5 hours before cell lysis. Protein concentrations were determined by Bradford 
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Assay (Bio-Rad). 20 μg of protein lysate was loaded into each well. The antibodies used: Nrf2 
(Santa Cruz, SC-722), Lamin B (Santa Cruz, SC-6216), p-AKT (Ser473) (Cell Signaling, 
9271S), AKT (Cell Signaling, 9272S), PTEN (D4.3) (Cell Signaling, 9188S), GAPDH (Novus 
Biologics, NB-300-221). Imaging and quantification of blots was performed by Chemi Doc XRS 
imaging system (BioRad).  
3.4 RESULTS 
3.4.1 WA induces Nrf2 signaling in MEF 
Treatment of wild-type MEF with graded doses of WA for 20 hours showed a dose-
dependent induction of NQO1 and HO-1 transcripts (Figure 3.1A and B). WA induced NQO1 
transcripts in WT MEF with a 200 nM response doubling concentration (referred to as CD value 
hereafter) suggesting high potency. This induction was not observed in Nrf2-knockout MEF 
suggesting that WA enhanced expression of cytoprotective enzymes in an Nrf2-dependent 
manner. Interestingly, HO-1 induction by 1 μM WA in wild-type MEF was >40-fold compared to 
DMSO control where 8-fold induction was observed in Nrf2-knockout MEF as well. HO-1 has 
been shown to be activated by multiple other transcription factors, such as NF-kB and AP-2 
[240] therefore it is likely that in the absence of Nrf2, WA can potentially target other such 
pathways. Additionally, Bach1 has been shown to exert repressive activity on transcriptional 
activation of HO-1 [241]. The very high transcriptional activation of HO-1 by WA may therefore 
be associated with alterations in Bach1 inhibition. Nrf2 nuclear translocation by 1 μM WA 
compared to 25 nM CDDO-Im was measured by blotting for Nrf2 protein expression in the 
nuclear fraction of wild-type MEF treated with the pharmacologic agents for a short time period 
(Figure 3.1C and D). At 1 hour, a 2.5 fold increase in nuclear Nrf2 was observed by WA 
 72 
compared to CDDO-Im. This trend seemed to be reversed after 3 hours where more nuclear 
Nrf2 was detected in the CDDO-Im-treated cells as compared to WA-treated cells. The more 
persistent nuclear import that occurs within 6 hours by CDDO-Im has been reported previously 
[238]. From these results, it was evident that the WA-induced Nrf2 nuclear translocation was 
much more rapid compared to CDDO-Im suggesting potential differences in pharmacokinetics 











Figure 3-1. WA induces Nrf2 signaling in mouse embryonic fibroblasts in vitro 
Transcript induction of A) NQO1 B) HO-1 in wild-type and Nrf2-knockout MEF with graded 
doses of WA (0-1 μM). DMSO was used as the vehicle control. RNA was isolated 20 hours post 
WA treatment. GAPDH was used as the housekeeping control. C) Western blot showing Nrf2 
protein expression in the nuclear fraction of wild-type MEF with pharmacologic agent treatments 
(1: Control, 2: 25 nM CDDO-Im after 1 hour, 3: 1 μM WA after 1 hour, 4: 25 nM CDDO-Im after 
3 hours, 5: 1 μM WA after 3 hours). Lamin B was used as the loading control. 20 μg of protein 
lysate was loaded per well. D) Quantification of densitometry of 3 replicate western blots 
representing C. All values are mean ± SEM (n=3). *p<0.05 (Student’s t-test). 
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3.4.2 WA induces Nrf2 signaling in human mammary cells 
To further evaluate the potential of WA to induce Nrf2 signaling, another in vitro system 
was utilized. Human mammary cells were used in order to determine if the initial hypothesis 
held valid not only for murine systems but also for human cells. In these experiments, 
comparisons were made between WA, CDDO-Im and sulforaphane to extrapolate the 
understanding of well-characterized Nrf2 inducers such as CDDO-Im and sulforaphane to a 
novel Nrf2 inducer, WA. Treating Nrf2 reporter MCF7 cells with 1 μM WA, 25 nM CDDO-Im and 
10 μM sulforaphane showed that all three inducers followed similar time-courses to activate Nrf2 
signaling wherein statistically significant induction was first observed after 10 hours of treatment 
followed by the highest observed induction seen at 24 hours (Figure 3.2A). Treating normal 
mammary epithelial MCF10A cells with graded doses of the 3 inducers brought forth interesting 
points. First, it appeared that highest induction of NQO1 in MCF10A cells required 0.7 μM WA 
(Figure 3.2B). In MCF10A cells, sulforaphane sustained a low (approximately 2-fold) but steady 
pattern of NQO1 mRNA induction compared to WA, which peaked at 0.7 μM to about 8-fold 
induction of NQO1 transcripts compared to DMSO control but dropped rapidly by 3 μM. This 
drastic drop in NQO1 induction was in part due to cytotoxicity of WA, evaluated by decreased 
cell viability at concentrations > 3 μM (data not shown; assessed by trypan blue exclusion). In 
wild-type MEF, a similar trend was observed where concentrations > 3 μM caused cell death 
(data not shown). These results are in agreement with previous publications where 2 μM WA 
caused suppression of vimentin expression in MCF10A cells [242] and 2 μM  WA did not cause 
G2 and mitotic arrest [139] suggesting that this concentration of WA was likely not cytotoxic to 
MCF10A cells. The effect of using a higher concentration than 2 μM was not assessed in these 
studies. Comparing CD values for each inducer, it was evident that WA (CD=80 nM) is much 
more potent than sulforaphane (CD=1.5 μM) in MCF10A cells in inducing NQO1 transcription.   
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Figure 3-2. Effect of WA on induction of Nrf2 signaling in human mammary cell lines 
compared to prototypical Nrf2 inducers.  
A) Relative luciferase activity in Nrf2 luciferase reporter MCF7 cells treated with 1 μM WA, 25 
nM CDDO-Im or 10 μM sulforaphane for 0, 6, 10 or 24 hours. B) NQO1 transcript induction in 
normal human mammary epithelial MCF10A cells treated with either 25 nM CDDO-Im or graded 
doses of WA/ sulforaphane (0-3 μM) for 20 hours. GAPDH was used as the normalization 
control for quantitative Real-time PCR. All values are mean ± SEM (n=3). *p<0.05.  
3.4.3 WA induces Nrf2 signaling in MEF independent of Keap1 
Keap1 & Nrf2 double deficient MEF transfection studies revealed important mechanistic 
details about Nrf2 signaling induction by WA. Transfecting 5 ng of Nrf2 alone induced NQO1-
ARE-Luciferase activity given the absence of Keap1 (Figure 3.3A). This induction was halted 
when 2.5 ng Keap1 was introduced suggesting the prominent role of Keap1 in inhibiting Nrf2 in 
this system. In the presence of Keap1, both CDDO-Im and sulforaphane were able to reverse 
the suppressive effect of Keap1 expression by inducing luciferase activity by >60%. However, 
WA treatment was not able to recover the inhibitory effect of Keap1. In the absence of Keap1 
and the presence of 5 ng of Nrf2, WA was able to induce luciferase activity by approximately 
1.5-fold compared to DMSO control (DMSO control fold change ~4, WA fold change ~ 6; data 
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not shown) suggesting that WA is able to induce Nrf2 signaling in this system. This was a hint 
that WA, unlike CDDO-Im and sulforaphane, was working independent of Keap1. To further 
evaluate whether WA is Keap1-independent, NQO1 transcript induction capacity of WA was 
compared in wild-type MEF, Nrf2-knockout MEF, Keap1-knockout MEF and Keap1 & Nrf2 
double-deficient MEF. NQO1 induction was not only observed in wild-type but also in Keap1-
knockout MEF (Figure 3.3B). In Keap1-knockout MEF, basal NQO1 was higher similar to what 
has been documented by others in Keap1flox/flox::AlbCre mice [33] and Keap1-knockout MEF 
[61]. WA (1 μM) induced NQO1 mRNA expression by approximately 1.5-fold in Keap1-knockout 
MEF as compared to 6.5-fold in wild-type MEF. Given the already high and possibly saturated 
levels of NQO1 in Keap1-knockout MEF, a 1.5-fold induction of transcripts can be viewed as a 
modest increase. Corroborating the idea that NQO1 induction by WA was Nrf2-dependent but 
Keap1-independent, induction was not observed in either Nrf2-knockout MEF or in Keap1& 









Figure 3-3. Mechanisms of Nrf2 induction by WA.  
A) Relative luciferase activity in Keap1/ Nrf2 double-disrupted MEF transfected with 5 ng pCMV 
Nrf2, 2.5 ng wild-type pCMV Keap1 and treated with either DMSO control, 3 μM WA, 25 nM 
CDDO-Im or 10 μM sulforaphane for 20 hours. B) NQO1 transcript induction in Keap1-deficient, 
wild-type, Nrf2-deficient and Keap1 & Nrf2 double-deficient MEF with graded doses of WA (0-3 
μM), 20 hours post-treatment. GAPDH was used as the housekeeping control for quantitative 
real-time PCR. All values are mean ± SEM (n=3). *p<0.05 (Student’s t-test). 
 
3.4.4 Inhibition of PI3K signaling attenuates Nrf2 signaling induction by WA 
Given the Keap1-independent induction mechanism of Nrf2 by WA, possible other 
pathways of Nrf2 regulation had to be considered in order to understand the mode of action of 
WA further. Pharmacologically inhibiting PI3K with LY294002 in both wild-type and Keap1-
knockout MEF resulted in dampening of NQO1 transcription (Figure 3.4A and B). In wild-type 
MEF, pre-treatment with 25 μM LY294002 for 1 hour prior to co-treatment of 25 μM LY294002 
and 1 μM WA resulted in approximately 50% lower induction of NQO1 transcripts compared to 
pre-treatment with DMSO control for 1 hour prior to co-treatment with DMSO control and WA. In 
 78 
Keap1-knockout MEF, a similar trend was observed, although not statistically significant. This is 
likely due to the already high levels of NQO1 present at basal state in these cells. No significant 
induction or inhibition of NQO1 or HO-1 resulted from the treatment of LY294002 alone in either 
cell type. Fold change of HO-1 transcripts in both wild-type and Keap1-knockout MEF were 
about 50% lower with pre-treatment of LY294002 (Figure 3.4C and D). Collectively, these 
results implied that WA modulated PI3K signaling in order to induce the Nrf2-ARE response. 
However, the fact that LY294002 treatment could not completely abrogate Nrf2 target gene 
induction by WA indicated the possibility that PI3K signaling was only partially responsible for 
regulating WA-mediated Nrf2 induction. It is also likely that silencing an important upstream 
signaling molecule such as PI3K could give rise to the activation of compensatory pathways that 
possibly feeds into the Nrf2 signaling cascade.  
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Figure 3-4. PI3K-dependent cytoprotective enzyme induction in wild-type and Keap1-
deficient MEF  
Cells were treated with DMSO control, 1 μM WA, 25 μM LY294002 or both 1 μM WA and 25 μM 
LY294002. A) NQO1 expression in wild-type MEF. B) NQO1 expression in Keap1-deficient 
MEF. C) HO-1 expression in wild-type MEF. D) HO-1 expression in Keap1-deficient MEF. All 
cells were pre-treated with DMSO/ kinase inhibitor for 1 hour followed by co-treatment with 
DMSO/kinase inhibitor and DMSO/ WA for a further 8 hours before RNA isolation. All values 
were normalized to DMSO only control for each cell type. All values are mean ± SEM (n=3). 
*p<0.05.  
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3.4.5 In vitro WA treatment modulates downstream effectors of PI3K signaling 
To further investigate the involvement of PI3K signaling in WA-mediated Nrf2 induction, 
activation of AKT was assessed by measuring expression of proteins important for PI3K 
signaling. PI3K has been shown to phosphorylate and activate AKT directly [243] and indirectly 
[244], making phosphorylated AKT a reliable marker of PI3K pathway activation. In wild-type 
MEF treated with WA, higher levels of p-AKT were observed compared to control treated cells 
(Figure 3.5). However, it must be noted that this level of enhanced expression is not significant, 
likely related to the fact that a relatively longer WA exposure time (6 hours) was used. Having 
observed Nrf2 nuclear translocation at 1 hour post-WA treatment, it is likely that these upstream 
phosphorylation events occur much earlier, presumably 15-30 minutes post-exposure. 
Phosphorylated AKT was markedly lowered in cells that were pre-treated with LY294002 for 1 
hour followed by co-treatment with LY294002 and DMSO. In cells that were pre-treated with 
LY294002 for 1 hour followed by co-treatment with LY294002 and WA, phosphorylated AKT 
levels were much lower, indicating that pre-treatment with PI3K inhibitor, LY294002 halted the 
activation of downstream targets of the PI3K pathway. In Keap1-knockout MEFs, the same 
trend was not observed where p-AKT levels appeared to be lower with WA treatment compared 
to DMSO control, suggesting that inherent differences between wild-type and Keap1-knockout 
MEF may contribute to their differential responses to WA-mediated AKT activation. Interestingly, 
WA has been shown to activate AKT in some cell lines [174] whereas in others the opposite 
effect has been observed [245] [246]. In broader terms, inhibition or activation of AKT by WA 
may be a cell type-specific phenomenon, which may or may not directly correlate with 
downstream Nrf2 activation.  
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Figure 3-5. Protein expression of molecules involved in PI3K signaling  
Wild-type MEF were treated with DMSO control, 1 μM WA, 25 μM LY294002 or both 1 μM WA 
and 25 μM LY294002. Cells were serum-starved overnight and pre-treated with DMSO/ kinase 
inhibitor for 1 hour and co-treated with DMSO/kinase inhibitor and DMSO/WA for a further 6 
hours. 20 μg of protein lysate was loaded per well. p-AKT, AKT and PTEN were detected by 
western blotting. GAPDH was utilized as a loading control.  
 
GSK3 is another important downstream effector of PI3K signaling where phosphorylation 
of AKT has been shown to deactivate GSK3 [247]. Furthermore, a key role of GSK3 in 
regulating Nrf2 has emerged in the recent years where GSK3 has been shown to phosphorylate 
serine residues of the Neh 6 domain of Nrf2, allowing for its interaction with β-TrCP [110]. 
Therefore, active GSK3 essentially has a repressive effect on Nrf2 induction. Using SB216763, 
a pharmacologic inhibitor of GSK3, the role of GSK3 in WA-mediated Nrf2 induction was 
evaluated. No changes in NQO1 transcription was observed in wild-type MEFs that were pre-
treated with the GSK3 inhibitor prior to co-treatment with GSK3 inhibitor and WA (Figure 3.6A). 
The same observation was made in luciferase activity when Nrf2 luciferase reporter MCF7 cells 
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were pre-treated with GSK3 inhibitor before co-treatment with WA (Figure 3.6B). LY294002 was 
utilized as a positive control where inhibiting PI3K was associated with a dampening of Nrf2 
induction by WA in both wild-type MEFs as well as Nrf2 reporter MCF7 cells. SB216763 in 
contrast did not have the same effect, possibly due to the fact that WA was in fact activating 
PI3K to turn off GSK3 activity, which ultimately leads to Nrf2 induction. In order to corroborate 
this data, kinase activity of both PI3K and GSK3 could be utilized to show exactly whether WA-
mediated mechanisms act on catalytic activity of these kinases.  
 
 
Figure 3-6. Effects of inhibiting GSK3 compared to inhibiting PI3K on WA’s ability to 
induce Nrf2 signaling.  
25 μM LY294002 and 20 μM SB216763 were used A) NQO1 transcript induction in wild-type 
MEF. B) Relative luciferase activity in Nrf2 luciferase reporter MCF7 cells. All cells were pre-
treated with DMSO/ kinase inhibitors for 1 hour followed by co-treatment with DMSO/kinase 
inhibitor and DMSO/ WA for a further 8 hours before RNA isolation or luciferase assay. All 
values are mean ± SEM (n=3). *p<0.05.  
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3.5 DISCUSSION 
This study was designed to evaluate the mechanistic details of Nrf2 induction by WA. As 
demonstrated in Chapter 2, WA elicits a profound protective effect that is Nrf2-dependent 
against APAP hepatotoxicity in wild-type and Nrf2flox/flox mice but not in Nrf2-knockout or 
Nrf2flox/flox::AlbCre mice. Using in vitro tools, we have shown that WA induces Nrf2-dependent 
cytoprotective enzyme expression as well as Nrf2 nuclear translocation (Figure 3.1). 
Furthermore, we also reveal that WA is more potent and efficacious than sulforaphane in human 
mammary epithelial MCF10A cells (Figure 3.2), a finding that needs further validation and could 
have important implications in preventing disease in human populations. Surprisingly, our 
studies indicated that WA works in a Keap1-independent manner to induce Nrf2 signaling 
(Figure 3.3). Our subsequent experiments suggested that PI3K-AKT-GSK3 signaling plays a 
partial role in this mechanism (Figure 3.4, 3.5 and 3.6). Further experimentation is required to 
determine the exact molecular events involved and whether actions upstream of PI3K signaling 
(such as modification of PTEN or oxidative stress-mediated events) are responsible for 
triggering the activation of this pathway.  
Several types of cellular stresses (oxidative stress, shear stress, ER stress, 
inflammatory stress) as well as many classes of molecules can activate Nrf2 signaling [35]. 
Binding to 3 major reactive cysteines of Keap1 (Cys 151, Cys 273 and Cys 288) has been 
proposed as the mechanism of action for electrophilic pharmacological agents. Here, we have 
shown that WA induces Nrf2 signaling in a Keap1-independent manner (Figure 3.3). There are 
important implications of this finding, especially given the recent findings of Keap1 mutations in 
several types of cancers [248] [249] . Thus, relying on compounds that exclusively bind to 
cysteine residues of Keap1 may not necessarily provide an advantage in preventing certain 
types of cancers. While key cysteines that sense thiol-reactive compounds have thus far not 
been identified to be mutated in cancers, it is likely that mutations in other sites of the Keap1 
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molecule could have effects on the reactive cysteines as well. Encouragingly, recent studies 
have classified Nrf2 inducers into several classes including one that does not involve the key 3 
reactive cysteines [72]. According to this classification, compounds such as DEM, sulforaphane, 
CDDO-Im and  t-BHQ are Cys151-prefering; 15d-PGJ2 is Cys288 preferring; OA-NO2, 4-HNE, 
AS3+ are Cys151/273/288-prefering; PGA2, Cd
2+, Zn2+, Dex-Mes, H2O2 are Cys151/273/288-
independent. However, these findings are not without contradictions. Interestingly, OA-NO2 was 
shown to be C151-independent where the role of C273 and C288 was not evaluated [250]. 
Furthermore, in contrast to the finding that AS3+ was Cys151/273/288-preferring by Saito et al., 
sodium arsenite was shown to work completely independent of Cys151 in another publication 
[251]. Whether Cys151/273/288- independent compounds function independent of Keap1 as a 
whole, or whether they target other less studied cysteines of Keap1 was not identified in this 
study. Site directed mutagenesis has been the preferred method used to determine cysteine 
reactivity of compounds but it introduces several challenges [252]. In addition to not binding 
thiol-reactive chemicals, mutant Keap1 molecules may have differential Keap1 activity and may 
also alter secondary signal transduction pathways as a result of the mutation itself. Collectively, 
research to date highlights the complexity of Nrf2 inducing agents, specifically in terms of their 
exact targets and requires further exploration. 
One interesting question pertaining to many studies that have shown “alternative” 
mechanisms of Nrf2 activation by pharmacologic agents is whether they in fact work 
independent of Keap1 or whether other molecules are hit as the result of off-target effects. 
Some agents such as nordihydroguaiaretic acid (NDGA) that exclusively work independent of 
Keap1 to induce Nrf2 signaling have been identified from evidence that NDGA activates Nrf2 
signaling in both wild-type and Keap1-disrupted cells [112]. Interestingly, it was recently shown 
that pharmacologic inhibitor of Nrf2, brusatol acts independent of Keap1 [253]. A component 
used in traditional Chinese medicine, baicalein was shown to work in both Keap1-dependent 
and independent mechanisms [254]. However, Keap1-dependence was shown by increased 
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proteasomal degradation of Keap1 by baicalein but research by others points in the direction 
that Keap1 is exclusively degraded by the autophagasome and not the proteasome [32]. 
However, it cannot be disregarded that these two pathways are not necessarily mutually 
exclusive since inhibition of autophagy leads to aggregation of proteins that are degraded by the 
ubiquitin-proteasome pathway [255]. Another method by which pharmacologic compounds can 
induce Nrf2 was showcased by sphingosine kinase inhibitor SKI-II where this compound 
repressed Keap1 activity by forming Keap1 dimers [256]. This type of mechanism is not 
completely independent of Keap1. However, mechanisms such as this that may not involve 
thiol-reactive chemicals directly binding to cysteine residues of Keap1, provide interesting 
insight into the multitude of ways Nrf2 signaling can be induced. Similar to observations made 
by Lau and colleagues with As3+ [251], fenofibrate, a potent PPARα-agonist induced Nrf2 via 
upregulating p62 that lead to increased autophagy-mediated degradation of Keap1 [257], 
suggesting that direct binding to Keap1 may not be the only mechanism of activating Nrf2 
signaling.  
In addition to not working via Keap1, WA appears to target PI3K signaling in order to 
activate Nrf2. Markedly lower NQO1 and HO-1 transcript induction in wild-type and Keap1-
knockout MEF pre-treated with LY294002 prior to co-treatment with LY294002 and WA (Figure 
3.4) serves as a direct attestation to this. Furthermore, LY294002 inhibits WA’s capacity to 
activate AKT in wild-type MEF (Figure 3.5) suggesting that PI3K pathway is definitely targeted 
by WA. Modulation of PI3K signaling upstream of Nrf2 by other pharmacologic agents has been 
shown in the past [112] [258]. PI3K inhibitors (LY294002 and wortmannin) were shown to block 
Nrf2 nuclear translocation in neuroblastoma cells [93]. Some agents such as curcumin appear 
to induce Nrf2 signaling independent of PI3K where HO-1 induction by curcumin was completely 
inhibited by LY294002 but not by wortmannin. One explanation for these seemingly differential 
responses to PI3K inhibition maybe that LY294002 blocks not only PI3K signaling but also 
casein kinase 2 [259]. Although there are advantages of wortmannin such as higher potency 
 86 
(50-100 nM to inhibit PI3K signaling), it has also been shown to inhibit other kinases such as 
PLK1 [260]. Moreover, the fact that wortmannin is unstable in aqueous solution prompted 
LY294002 to be used as the PI3K inhibitor of choice in these experiments [261]. In another 
study, it was shown that induction of aldose reductase and Nrf2 nuclear translocation by 15 μM 
curcumin was partially lost with LY294002 [262].  
While prototypical Nrf2 inducers with high specificity and high potency such as 
sulforaphane and CDDO-Im have been considered to target cysteine residues of Keap1 by 
direct binding, their potential to activate other pathways have also been evaluated. CDDO-Im as 
well as other synthetic triterpenoids has been shown to induce PI3K signaling as well as 
enhance expression of phosphorylated AKT [107]. In addition, CDDO-Bt (biotinylated CDDO) 
was shown to directly bind to cysteine 124 of PTEN to inhibit its phosphatase activity suggesting 
that triterpenoids can not only selectively bind to cysteines of Keap1 but much rather exert their 
thiol-reactive effects on low pKa cysteines on other molecules as well.  It is worth noting that 
biotinylation of the CDDO molecule significantly altered its structure making it bulkier, 
presumably changing its biochemical reactivity. Also CDDO-Im inhibited PTEN lipid 
phosphatase activity, however this effect was exerted at much larger concentrations of CDDO-
Im (0.5-5 μM) compared to 25-100 nM used to induce Nrf2 signaling. Sulforaphane too has 
been shown to activate PI3K to induce Nrf2 signaling [263],[264] at concentrations comparable 
to those used to induce Nrf2 signaling (1-10 μM). Taken together, it is likely that PI3K signaling 
works upstream of Nrf2 signaling as a major modifier. Whether PI3K is involved in regulating 
Nrf2 under high oxidative stress, when Keap1-based Nrf2 regulation is minimized, is currently 
not known.  
Being able to efficiently respond to damage by free radicals is an inherent part of cellular 
health. Oxidative stress induction by WA has been evaluated in several different models 
[175],[167;174]. The mechanism of action of Nrf2 induction by ROS/RNS has not been 
comprehensively dissected apart thus far, given the challenges involved in measuring short-
 87 
lived cellular events such as ROS/RNS generation. Nevertheless, it has been shown that H2O2 
activates multiple signaling pathways within the cell including MAPK [265], and NF-kB in some 
cell lines [266]. Small electrophilic molecules that are revered as Nrf2 inducers coincidentally 
also exploit “pro-oxidant” properties by which they essentially bind Keap1. Indirect evidence 
suggests that thiol-rich proteins such as Keap1 may act as a sensor for free radicals to activate 
downstream cytoprotective pathways. Oxidants such as H2O2, SpNO, HOCl result in disulfide 
bond formations between Cys226 and Cys613 (intramolecular) and between Cys151 
(intermolecular) of Keap1 which may potentially assist in the conformational change that no 
longer favors Nrf2-Keap1 binding [267]. H2S also forms a disulfide bond between Cys226 and 
Cys613 of Keap1 which leads to Nrf2 induction [268]. Therefore, induction of Nrf2 may not 
necessarily be the result of direct binding of electrophiles to reactive cysteines of Keap1 but 
involve other mechanisms that give rise to conformational changes in Keap1. However, this may 
depend of how much ROS/ RNS there is in that high levels of free radicals may cause them to 
act as damaging agents as opposed to signaling agents. Glutathione conjugation is a classic 
biotransformation pathway utilized by the cell to scavenge free radicals. The oxidant, S-S bis-
glutathione disulfide, GSSG has been shown to directly bind Keap1 cysteines [269]. 
Furthermore, recent data suggests that there is significant overlap between Keap1/Nrf2 
signaling and the two major disulfide reductase systems, Glutathione (GSH) and thioredoxin 
(Trx) [270]. Therefore, it is likely that the aforementioned pathways communicate with each 
other to simultaneously scavenge free radicals and also activate cytoprotective pathways to 
prevent oxidant damage. Whether WA is rapidly biotransformed within the cell by either  GSH/ 
Trx or other reactions (hydrolysis of the epoxide group of WA by epoxide hydrolase) is currently 
unknown. Interestingly, Cys151-preferring sulforaphane has been shown to be involved in 
generating oxygen free radicals in the mouse lung as measured by EPR spectroscopy [271]. 
CDDO-Im (1 μM) too induced ROS (measured with H2DCFDA) in W780 breast cancer cells 
[158]. Thus, it is possible that depending on the dose of the Nrf2 inducing electrophile, it alone 
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could generate an environment that is higher in free radicals, allowing for Keap1 and other 
signaling molecules that are targeted by them to be inactivated. Given the mounting evidence 
that WA generates oxidative stress in the cellular environment, it is likely that this leads to 
activating multiple signaling schemes that presumably work upstream of Nrf2.  
 
Figure 3-7. Putative signaling pathways activated by WA to induce Nrf2 independent of 
Keap1. 
 
PTEN is an essential molecule with phosphatase activity that blocks PI3K signaling by 
inhibiting PIP3-dependent processes such as AKT activation and thereby inhibiting cell survival, 
growth and proliferation. From the standpoint of cancer and tumorigenesis, PTEN inhibition 
plays a detrimental role as seen with prenatal death of PTEN-knockout mice and the 
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observation that more than 2700 PTEN mutations have been observed in 28 type of human 
tumors [272].  However, under normal conditions, PTEN seems to be playing an important role 
in regulating cellular homeostasis acting as a redox sensing switch that either activates or 
deactivates PI3K signaling. This finding directly supports the notion that short-term suppression 
of PTEN could potentially be valuable in certain conditions, such as nerve injury [273]. H2O2 can 
reversibly inactivate PTEN where oxidized PTEN shows the formation of disulfide bond between 
Cys71 and Cys124 [274]. However, overexpression of antioxidant enzymes such as SOD and 
catalase have been associated with production of H2O2 and activated AKT signaling mediated 
by oxidized PTEN [275]. The redox-sensitive interplay between PTEN and PI3K signaling is 
involved in the pathogenesis of hypertension [276]. Oxidants such as H2O2 inactivate PTEN to 
activate downstream signaling cascades driven by PI3K [277]. Age-dependent down regulation 
of PI3K signaling is associated with increased susceptibility to oxidative stress [278]. 
Collectively, existing data suggests that PTEN can be reversibly deactivated by two major 
mechanisms. 1) Electrophiles directly binding to its reactive cysteines 2) Binding of reactive 
species (such as a reactive metabolite of WA or H2O2) that accumulate in the cellular 
environment during and after a stress event (Figure 3.7). It is likely that WA affects both these 










4.0  USING WA TO PROTECT MICE AGAINST DIET-INDUCED STEATOHEPATITIS 
4.1 INTRODUCTION 
4.1.1 Non-alcoholic fatty liver disease (NAFLD) 
NAFLD is currently the most common form of chronic liver disease in adults living in 
developed nations [279]. This high prevalence of NAFLD is attributable to rising rates in obesity 
and type II diabetes in many regions of the world. The progression of the disease is 
characterized by distinct phases of fatty liver, ranging from simple steatosis to non-alcoholic 
steatohepatitis (NASH) as illustrated in figure 4.1. If not intervened, NASH has been shown to 
advance to hepatic cirrhosis followed by hepatocellular carcinoma [280]. Diagnosis of NAFLD 
typically incorporates liver imaging (ultrasound, MRI), biopsies as well as some biomarker 
testing (eg. ALT, AST). Usually the degree of inflammation and fibrosis is utilized to determine 







Figure 4-1. Disease progression of NAFLD in humans.  
Modified from Mehal et al. Gastroenterology & Hepatology 2013 [282]. Permission to reproduce 
obtained via Copyright Clearance Center, Rightslink® 
The molecular events that contribute to the pathophysiology of NAFLD are not 
completely understood. A “two-hit” theory has been proposed suggesting that metabolic 
alterations such as fat accumulation in hepatocytes and insulin resistance (first hit) is followed 
by inflammatory insults caused by cytokine secretion, enhanced NF-kB signaling and increased 
ROS/RNS (second hit) [283]. The antioxidant response has been shown to play an important 
role in the development of steatosis where GCLC deletion in hepatocytes resulted in steatosis in 
mice causing death at 1 month [284]. Along with other pathologies, liver steatosis and enhanced 
generation of ROS was detected in Endothelial PAS domain-containing protein 1 (Epas1) 
knockout mice [285]. Additionally, neonatal steatohepatitis has been observed in adenosine 
kinase knockout mice [286]. Interestingly, liver specific deletion of Nrf1 leads to steatosis 
coupled with heightened oxidative stress as well as inflammation and fibrosis followed by 
hepatic cancer [287]. Currently, there are no reports of Nrf2 deletion leading towards a 
spontaneous steatosis phenotype in mice, but the function of Nrf2 in protecting against steatosis 
and steatohepatitis has been studied with diet-induced NAFLD models and are discussed in a 
later section. 
Several mouse models, both genetic and diet-induced, have expanded our 
understanding of NAFLD-associated pathologies and molecular mechanisms involved. Some of 
these models are summarized in Table 4.1. While these models do not exactly replicate human 
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NAFLD, they provide valuable tools to evaluate potential molecular targets and also test 
probable preventive or therapeutic agents against NAFLD. Given that NAFLD comprises a 
diverse spectrum of different pathologies, it is likely that multiple signaling mechanisms are 
involved. As is evident from Table 4.1., the models of NAFLD harbor fundamental differences to 
each other but also carry their own merits that make them desirable study models.   
 
Table 4-1. Summary of select mouse models of NAFLD with their pathological 
characteristics.  




Steatosis Steatohepatitis Fibrosis 













Genetic No No Yes Yes Yes 
High fat 
 
Dietary Yes Yes Yes Yes (mild) Yes 
MCD 
 
Dietary No Hepatic 
only 
Yes Yes (severe) Yes 
Cholesterol 
&  cholate 
diet 
 
Dietary No Hepatic 
only 
Yes Yes Yes 
Fructose 
 
Dietary No Yes Yes No/Yes No 
Modified from Takahashi et al. World Journal of Gastroenterology 2012 [288]. Open access 
journal. 
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4.1.2 Methionine-choline deficient (MCD) diet-induced NAFLD 
The pathogenesis of MCD diet-induced NAFLD is illustrated in Figure 4.2. One of the 
key advantages of MCD-diet induced NAFLD is that, severe steatohepatitis can be observed in 
mice within a relatively short period of time (2-4 weeks) on the diet as compared to 3 months to 
develop the first signs of fatty liver with high fat diet [289]. While this is a useful model to study 
NAFLD, the unique nature of the disease observed with MCD diet (non-diabetic and non-obesity 
phenotype) makes it challenging to translate into NAFLD observed in humans. The mechanism 
of onset of steatosis with MCD is attributable to impaired VLDL secretion due to lack of 
phosphotidyl choline synthesis. Mice on MCD diet lose weight, presumably due to 
hypermetabolism coincident with hepatic suppression of SCD-1 [290] as compared to other 
models of NAFLD where weight gain is typical. Unlike with spontaneous steatohepatitis, MCD 
diet-induced steatohepatitis does not show evidence of peripheral insulin resistance [291] but 
shows hepatic insulin resistance[292]. Interestingly, it has been shown that inhibition of 
triglyceride synthesis with diacylglycerol acyltransferase 2 antisense oligonucleotide (DGAT2 
ASO; 25 mg/kg, i.p., twice/week for 4 and 8 weeks) improved only hepatic steatosis but it 
worsened inflammation and fibrosis in male db/db mice [293] suggesting that triglyceride 
synthesis is possibly a marker of early stages of MCD-induced liver damage.  
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Figure 4-2. The progression and pathological characteristics of different phases of MCD 
diet induced NAFLD in mice.  
Diagram designed by Dushani Palliyaguru.  
 
Multiple plant-based agents and small molecules have been shown to have efficacy 
against either preventing or treating MCD diet-induced NAFLD. When male C57BL/6 mice were 
administered MCD diet for 10 weeks along with curcumin (25 μg/ mouse, i.p), lower steatosis, 
necroinflammation and fibrosis was observed compared to controls [294]. Administration of 
MCD diet supplemented with an ethyl acetate extract of Teucrium polium (equivalent to 0.5 g 
leaves powder/kg body weight/ day) to female N-Mary rats for 8 weeks, showed lower grade 
steatosis, hepatic ballooning and inflammation compared to animals on MCD diet supplemented 
with control [295]. In a similar study where MCD diet was supplemented with dandelion leaf 
extract (200 or 500 mg/kg body weight/ day) it was observed that significantly lower steatosis, 
necroinflammation was seen with both 200 and 500 mg/kg body weight/ day but lowered serum 
ALT and hepatic triglycerides were seen only with the 500 mg/kg body weight/ day group [296]. 
Interestingly, from existing evidence, pharmacologic agents are not able to provide complete 
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protection against MCD-diet induced liver injury, probably due to the enormity of liver damage 
caused by methionine and choline deficiency. Nevertheless, partial prevention of damage has 
been shown. Another limitation of studies with the aforementioned pharmacologic agents is that 
the exact molecular mechanisms by which they exert their protective action against MCD diet 
induced NAFLD have not been characterized. This is in part attributable to the fact that many of 
the pharmacologics mentioned above have multiple molecular targets.  
4.1.3 Nrf2 in MCD diet-induced NAFLD 
The protective role of Nrf2 in MCD diet-induced NAFLD has gained research interest in 
the recent years. It has been shown that systemic Nrf2 knockout mice exhibit heightened 
severity in steatosis as compared to wild-type controls after 2 weeks on MCD [297]. These mice 
also showed higher levels of oxidative stress as well as increased expression of NF-kB. This 
study was corroborated by another one shortly after, where it was shown that Nrf2 knockout 
mice displayed more rapid onset of steatohepatitis at both 3 and 6 weeks on MCD diet 
compared to wild-type counterparts [298]. Nrf2 overexpressing Keap1 knockdown (Keap1flox/flox) 
mice were protected against MCD-induced steatosis after 5 days on the diet [299]. When 
transgenic mice expressing a constitutively active Nrf2 construct in hepatocytes 
(AlbCre+/caNrf2+) were given MCD diet for 28 days, it was observed that these animals had 
significantly lower steatosis compared to controls [300]. Interestingly, these animals did not 
show lowered oxidative stress or inflammation. Even though multiple pharamacologic agents 
have been shown to have protective and/or therapeutic effects against MCD diet-induced 
NAFLD, classic Nrf2 inducers such as sulforaphane and CDDO-Im have not been tested so far 
in the MCD model.  
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4.2 HYPOTHESIS 
WA protects mice against MCD diet-induced steatohepatitis in an Nrf2-dependent manner 
4.3 METHODS AND MATERIALS 
Animals and husbandry  
Wild-type male C57BL/6J mice (25-33 g) were purchased from Jackson laboratories. 
Nrf2flox/flox, Nrf2flox/flox::AlbCre and Keap1flox/flox mice have been described in Chapter 2 and were 
bred in-house. All animals were 7-8 weeks at the beginning of the experiment. All animals were 
fed specific diets (see below) with ad libitum access to water. All experiments were performed in 
accordance with the guidelines of the Institutional Animal Care and Use Committee at University 
of Pittsburgh.  
Diets and experimental set up 
Control diet (A02082003B) and MCD-diet (A02082002B) were both purchased from 
Open Source diets. The only difference between the two diets was that the control diet had 3 g 
of L-methionine and 2 g of choline bitrartrate supplemented compared to 0 g of both 
components in the MCD-diet. Diet amounts were weighed before and after to ensure that the 
rates of consumption were equal for both diet groups. Animals were given a single dose of 7 
mg/kg WA (p.o.) one day prior to beginning the diets and every other day thereafter during the 
exposure to the special diets. Wild-type mice were on the diets for 2 weeks while all other 
genotypes were on the diet for 3 weeks as the latter experiment was extended by an additional 
week to determine if there were differential effects of a longer exposure to MCD diet. Body 
weight measurements were taken every other day. At the end of the diet period, animals were 
sacrificed and livers were harvested and weighed. For serum ALT measurements, blood was 
drawn by cardiac puncture and for histological analyses, livers were fixed in formalin or 
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prepared in frozen sections. Pieces of the liver were either snap-frozen for protein analysis or 
preserved in RNA Later (Ambion) for RNA extraction.  
Liver histology and liver triglycerides  
Formalin fixed liver sections were used for H & E staining. Frozen sections were utilized 
for Oil Red O staining. Hepatic triglycerides were quantified using Triglyceride Colorimetric 
Assay Kit (Cayman Chemical, 10010303) which is based on the enzymatic hydrolysis of 
triglycerides by lipase to glycerol and free fatty acids.  
RNA isolation and Real time PCR  
RNA from mouse liver homogenates was extracted and purified using an RNA extraction 
kit (5-PRIME). RNA integrity was confirmed by electrophoresis. Quantification of RNA 
concentrations was performed using spectrophotometry at 260 nm. cDNA was synthesized with 
the qScript system (Quanta Biociences). All primers were designed using Primer Bank software. 
Primer annealing temperatures were determined by semi-quantitative PCR with gradient 
temperature. Real time PCR was performed on a 242 Bio-Rad My-IQ machine (Applied 
Biosystems) with SYBR green (Bio-Rad). PCR efficiency was determined using a standard 
curve and the Pfaffl method was used for quantification of fold changes.  
4.4 RESULTS 
4.4.1 Mice on MCD diet lose body weight irrespective of WA administration 
Wild-type, Nrf2flox/flox and Nrf2flox/flox::AlbCre and Keap1flox/flox mice on MCD lost weight 
compared to their control diet counterparts. WA treatment did not appear to alter this phenotype. 
To ensure that this was not the result of differential food intake between the two diet groups, the 
amount of each diet consumed was measured and found to be the same (data not shown). 
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Percent body weight changes normalized to wild-type mice on control diet and DMSO treatment 
showed that MCD diet administration irrespective of DMSO or WA treatment resulted in 
statistically significant loss of body weight after 2 weeks (Figure 4.4). As described in the 
methods and materials section, wild-type animals were on the diets for 2 weeks while the other 
genotypes were on the diets for 3 weeks. This was because it was desirable to determine if 
there were differential effects of extending the diet for an additional week. Due to this, percent 
changes in body weight were calculated for the weight at the end of 2 weeks for all genotypes. 
Liver to body weight ratios were not significantly changed by either MCD diet or WA treatment 
(Figure 4.5). The only statistically significant differences in percent liver/body weight ratio 
observed were in Keap1flox/flox mice on control diet (5.5%) and MCD (6.2%) diet compared to 
wild-type mice on control diet administered DMSO (4.1%) (Figure 4.5). The larger percent liver 
weights of Keap1flox/flox mice are in agreement with previous publications [49]. Although not 
statistically significant, the general trend of Nrf2flox/flox::AlbCre livers having lower weights than 
Nrf2flox/flox and wild-type mouse livers was also observed here.  
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Figure 4-3. Body weight measurements of mice on MCD diet. 
A) wild-type B) Keap1flox/flox C) Nrf2flox/flox D) Nrf2flox/flox::AlbCre mice fed either control or MCD 
diets. Wild-type, Nrf2flox/flox , Nrf2flox/flox::AlbCre mice were also simultaneously gavaged with 
either DMSO or 7 mg/kg WA every other day for the entire duration of the diet exposure. Values 
are mean ± SEM (n>6 per group). Statistical significance determined by comparison of values to 




Figure 4-4. Percent body weight changes of mice either on control or MCD diet along with 
DMSO or 7 mg/kg WA (oral) administration at the end of 2 weeks.  





Figure 4-5. Percent liver to body weight ratios.  
Wild-type mice were sacrificed after 2 weeks of diet and treatment while all other mice were 
sacrificed 3 weeks after. *p<0.05.  
4.4.2 Minor protection provided by WA to wild-type and Nrf2flox/flox mice against MCD 
diet-induced liver damage 
All genotypes of mice that were on MCD diet showed extensive accumulation of lipids as 
observed in H&E stained liver sections compared to control diet counterparts (Figure 4.6). 
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Keap1flox/flox mice that were used as a negative control showed far less fat accumulation 
compared to other genotypes (Figure 4.8). In wild-type mice, liver damage was more severe 
away from the periportal regions where areas of normal hepatocytes were observed. While WA 
treatment did not completely protect against the accumulation of fat, it was observed that WA 
treated wild-type mice showed larger areas of normal hepatocytes in the periportal regions. The 
role of particular liver zones in NAFLD severity is not a well-understood phenomenon but it is 
thought that fat accumulation is generally accentuated in zone 3 [301], similar to what is 
observed here. Areas of inflammation were observed in both cases. In WA treated Nrf2flox/flox 
mice, far lesser number of fat vacuoles were observed compared to Nrf2flox/flox mice treated with 
DMSO. Mice with hepatocyte-specific deletion of Nrf2 showed less fatty changes compared to 
wild-type and Nrf2flox/flox mice, possibly due to the fact that these mice had transitioned into a 
different phase of NAFLD where fat accumulation was not as prominent. However, signs of 
fibrosis or cirrhosis were not observed in these animals through histological observations. WA 
treatment did not alter the phenotype observed in Nrf2flox/flox::AlbCre mice.  
Interestingly, Oil Red O stains (Figure 4.7 and 4.8) revealed that wild-type mice had the 
highest amount of lipid accumulation amongst the 4 genotypes of animals after 2 weeks of 
MCD. Nrf2flox/flox mice after 3 weeks on the MCD diet showed smaller and less pronounced 
accumulation of lipids in their livers compared to wild-type, presumably as a result of lower fatty 
change occurrence as MCD diet induced NAFLD progresses. The Oil red O staining of frozen 
liver sections showed that wild-type and Nrf2flox/flox mice on MCD diet treated with WA had lower 
lipid accumulation compared to mice treated with DMSO. However, this difference was 
apparently very minor as even WA-administered animals within these two genotypes did not 
show complete or even partial protection from the formation of lipid droplets as a result of the 
MCD diet. Interestingly, Nrf2flox/flox::AlbCre mice that were treated with WA did not show the 
seemingly lower lipid accumulation that was observed in the wild-type and Nrf2flox/flox mice 
suggesting that the minor amount of WA-mediated protection was not available when Nrf2 was 
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deleted in the hepatocytes.  Keap1flox/flox mice fed MCD diet had markedly lower hepatic lipid 
accumulation (Figure 4.8) compared to animals fed the control diet as observed through Oil Red 














Figure 4-6. H & E stains of liver sections. 
Livers were fixed in formalin. Images are under 10X magnification and are representative of 
n=6. A) wild-type MCD+DMSO. B) wild-type MCD + WA. C) Nrf2flox/flox MCD + DMSO. D) 
Nrf2flox/flox MCD + WA. E) Nrf2flox/flox::AlbCre MCD + DMSO. F) Nrf2flox/flox::AlbCre MCD + WA. 
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Figure 4-7. Oil Red O stains of liver sections  
Livers were frozen prior to processing and embedding. Images are under 10X magnification and 
are representative of n=6. Top left) wild-type MCD+DMSO. A) wild-type MCD+DMSO. B) wild-
type MCD + WA. C) Nrf2flox/flox MCD + DMSO. D) Nrf2flox/flox MCD + WA. E) Nrf2flox/flox::AlbCre 
MCD + DMSO. F) Nrf2flox/flox::AlbCre MCD + WA. 
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Figure 4-8. H & E and Oil Red O stains of liver sections of Keap1flox/flox mice.  
Livers were fixed in formalin for H&E and frozen for Oil Red O. Images are under 10X 
magnification and are representative of n=6. A) Control diet H&E. B) MCD diet H&E. C) Control 
diet Oil Red O. D) MCD diet Oil Red O. 
 
4.4.3 Biomarkers of NAFLD were unaltered by WA treatment 
Serum ALT of mice that were on MCD diet was significantly higher compared to their 
genotype counterparts on control diet (Figure 4.9A). Nrf2flox/flox and Nrf2flox/flox::AlbCre mice 
showed higher serum ALT compared to wild-type mice, possibly due to the fact that the former 
two genotypes were on the diet a week longer than the latter. Surprisingly, Keap1flox/flox mice 
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showed the highest levels of serum ALT, which was unexpected as these mice were utilized as 
a negative control for the experiment with the hypothesis that they would be protected against 
MCD-diet induced liver damage. When Zhang et al. evaluated serum ALT in Keap1flox/flox mice 
after 5 days on MCD diet, no significant difference was observed compared to wild-type mice on 
MCD diet [299]. However, given that Keap1flox/flox mice are protected against MCD diet induced 
fat accumulation, it is plausible that these mice may have slower progression of NAFLD 
compared to wild-type, Nrf2flox/flox and Nrf2flox/flox::AlbCre mice as WA treatment did not alter 
serum ALT levels in any of the genotypes significantly.  
 
Figure 4-9. Serum ALT measurements. 
Mice were wild-type, Keap1flox/flox, Nrf2flox/flox, Nrf2flox/flox::AlbCre mice fed either control or MCD 
diets. Wild-type, Nrf2flox/flox , Nrf2flox/flox::AlbCre mice were also simultaneously gavaged with 
either DMSO or 7 mg/kg WA every other day for the entire duration of the diet exposure. Serum 
was prepared by drawing blood via cardiac puncture after animals were anesthetized at the end 
of the experiment duration. Values are mean ± SEM (n>6 per group). Statistical significance 
determined by comparison of values to control for each genotype. * p<0.05. 
 
Hepatic triglycerides are considered to be an important marker of steatosis. As 
anticipated, hepatic triglycerides were observed to be the lowest in Keap1flox/flox mice fed the 
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MCD diet compared to other genotypes that were on the same regimen (Figure 4.10). This 
result was in agreement with histological observations. Significant differences between liver 
triglycerides of wild-type, Nrf2flox/flox and Nrf2flox/flox::AlbCre were not observed, possibly indicating  
the fact that all these animals progress to MCD diet-induced steatosis irrespective of Nrf2 
expression status in hepatocytes. In a previous study, Nrf2 knockout mice had higher total 
lipids, saturated fatty acids and polyunsaturated fatty acid in their livers compared to wild-type 
mice after being on MCD diet for 2 weeks [297]. During this study, WA treatment did not appear 
to change hepatic triglyceride levels in any of the genotypes on MCD diet suggesting that 
administration of WA was not able to retard the onset of steatosis.  
 
Figure 4-10. Hepatic triglycerides  
Mice were wild-type, Keap1flox/flox, Nrf2flox/flox, Nrf2flox/flox::AlbCre fed either control or MCD diets. 
Wild-type, Nrf2flox/flox , Nrf2flox/flox::AlbCre mice were also simultaneously gavaged with either 
DMSO or 7 mg/kg WA every other day for the entire duration of the diet exposure. Livers were 
snap-frozen prior to assessment of hepatic triglycerides. Values are mean ± SEM (n=5 per 
group). Statistical significance determined by comparison of values to control for each genotype. 
* p<0.05. 
 109 
4.4.4 Markers of inflammation are not altered by WA treatment 
Inflammation is an important characteristic of steatohepatitis. The up regulation of IL-6 
expression has been observed with MCD diet [296] and can be utilized as a marker of the 
progression from steatosis to steatohepatitis. Liver transcripts of IL-6 in wild-type mice that were 
either on control or MCD diets along with DMSO or WA treatment were assessed. MCD diet 
alone enhanced IL-6 transcripts in both treatment groups, where WA did not significantly alter 
these levels, suggesting that progression of steatosis to steatohepatitis marked by the presence 
of inflammation, under MCD diet was not attenuated by WA in wild-type mice.  
 
Figure 4-11. Hepatic IL-6 transcript induction  
Mice were wild-type on control or MCD diets along with DMSO or 7 mg/kg WA oral 
administration for 2 weeks. All values normalized to mean of control diet mice on DMSO 
treatment. GAPDH was used as a normalization control. Values are mean ± SEM (n=5 per 
group). *p<0.05.  
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4.4.5 MCD diet induces NQO1 transcripts in the liver 
NQO1 mRNA in livers of wild-type mice that were on either control or MCD diet along 
with DMSO or WA treatment was assessed. In the control diet group, WA induced NQO1 by 
approximately 2-fold compared to mice treated with DMSO. Interestingly, MCD diet alone 
induced NQO1 by approximately 10-fold, suggesting that NQO1 induction in this case is an 
adaptive response to the oxidative stress caused by the MCD diet (Figure 4.12). Mice on MCD 
diet that were treated with WA did not show a significantly different induction of NQO1 
compared to mice that were on MCD diet treated with DMSO. Zhang et al. showed that NQO1 
transcripts were higher in Keap1-knockdown mice that were fed MCD diet for 5 days compared 
to their genetic counterparts fed a control diet [299]. In this study, it was also shown that Keap1-
deficient mice were more resistant to damage caused by the MCD diet. Enhanced nuclear 
translocation of Nrf2 by the MCD diet in Keap1-deficient mice compared to wild-type mice was 
also observed, suggesting that although Nrf2 induction is a response to the oxidized 
environment created by Methionine Choline deficiency, silencing Keap1 genetically provides the 
liver with NQO1-mediated protection against liver damage from MCD diet. It is likely that, a 
pharmacologic agent such as WA is not able to induce the same protective effect of genetic 
enhancement of Nrf2 signaling in the MCD model.  
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Figure 4-12. NQO1 transcript induction in wild-type mice on control or MCD diets along 
with DMSO or 7 mg/kg WA oral administration.  
4.5 DISCUSSION 
Although serum ALT is utilized as an initial predictor of the disease, studies have shown 
that serum ALT levels maybe normal in 78% of patients with NAFLD [302]. Furthermore, the 
entire spectrum of pathologies associated with NAFLD has been observed in patients with 
normal serum ALT values [303] making the predictive value of serum biomarkers in determining 
NAFLD status mostly unreliable. Furthermore, when Keap1 flox/flox mice were given MCD diet for 
5 days, they showed no difference in serum ALT compared to control Nrf2-knockout and wild-
type mice that were on MCD [299]. However, Keap1flox/flox mice did show lower hepatic 
triglycerides, overall lower fat accumulation, and higher expression of ARE genes. In this study, 
we saw that Keap1flox/flox mice showed lowered hepatic triglycerides and lowered lipid 
accumulation which are in line with previous publications.  
Although hepatic triglyceride amounts are widely utilized as an estimate of the degree of 
NAFLD, this alone is not adequate to determine the degree of damage, especially in the MCD 
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model. Triglycerides themselves do not pose hepatotoxicity in that triglyceride synthesis 
protects hepatocytes against lipotoxicity caused by the accumulation of free fatty acids [293]. 
Thus, generation of hepatic triglycerides may very well be a protective response. Furthermore, 
hepatic triglycerides have been shown to be lower in mice on MCD for 8 weeks compared to 
standard chow diet [304] suggesting that triglyceride content could be utilized as an accurate 
predictor of NAFLD only within certain stages of the disease, presumably only during the earlier, 
non-fibrotic phases.  Therefore, the comparison of multiple genotypes within the MCD diet as 
we have attempted here, poses a special challenge in that some genotypes may exhibit slower 
or faster progression of the disease. 
Several studies have shown the protective effects of pharamacologic agents against 
MCD diet. Some of the key differences between such studies and our study may help explain 
the discrepancies in observations. First, the route and frequency of agent administration 
presumably plays an important role in how the effects of the MCD diet can be counter-acted by 
a given compound. Many of the studies that showed protective effects with agents utilized 
intraperitoneal administration of the compound daily [305] [306], supplementation of the 
compound into the diet itself or supplementation of the compound into drinking water [307]. 
These protocols of administration could result in fundamentally different outcomes given the 
effects on absorption and metabolism.  
Second, different agents are likely to target different molecular pathways, resulting in 
differential biological outcomes. This could potentially be pivotal in a disease such as NAFLD 
that comprises of multiple stages that are essentially different to each other. Researchers have 
shown that certain agents specifically alter a given portion of NAFLD progression but not others. 
Probiotic VSL#3 was shown to attenuate fibrosis (by lower expression of TGF-β and matrix 
metalloproteinases) but not steatosis or steatohepatitis in C57BL6 mice fed MCD diet for 10 
weeks [307]. Co-administration of FXR agonist WAY-362450 with MCD diet did not prevent 
hepatic triglyceride accumulation or histological appearance of steatosis but showed marked 
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reduction in collagen deposition and fibrosis marker expression in C57BL/6 mice fed the diet for 
4 weeks [308]. Therefore, having a better understanding of the molecular pathways involved in 
steatosis, steatohepatitis and other NAFLD-related pathologies could potentially be useful in 
identifying preventive or therapeutic pharmacologic agents. No signs of fibrosis were observed 
in any of the genotypes of mice utilized in this study and histological analyses showed that 
animals on MCD were in the steatosis-steatohepatitis stage when they were sacrificed. 
Although WA was not able to successfully prevent the progression NAFLD during the stages of 
steatosis and steatohepatitis, further research needs to be carried out to determine whether it 
can potentially protect against progression of fibrosis under longer exposure to MCD diet (>4 
weeks).  
While hepatocyte injury is considered to be paramount for NAFLD, the role of other liver 
cell types such as Kupffer cells [309] and sinusoidal endothelial cells [310] have recently 
emerged. Kupffer cells are thought to recognize fatty changes occurring in neighboring 
hepatocytes and stellate cells via Toll-like receptors that activate an inflammatory signal 
cascade leading to cytokine secretion. TLR-4 mutant mice showed significantly lower lipid 
accumulation and injury from MCD diet compared to wild-type after 3 weeks on the diet [311]. 
Kupffer cell depletion by chlodronate blunted signs of steatohepatitis in these mice suggesting 
the underappreciated role of Kupffer cells in NAFLD. This may offer a plausible explanation to 
the fact that systemic Nrf2 knockout animals being more sensitive to MCD diet-induced damage 
compared to hepatocyte-specific Nrf2 knockout mice. Expression of Nrf2 in other liver cell types 
can possibly contribute to lowered fat accumulation hence the overall damage due to MCD 
could be greater in the Nrf2 knockout compared to Nrf2flox/flox::AlbCre.  
Overall, our study highlighted that WA alone is not sufficient to protect mice against 
MCD diet-induced NAFLD during the earliest phases of the disease. Given that MCD diet exerts 
an enormous amount of damage on hepatic homeostasis, and as a result activates Nrf2 
signaling as an adaptive response to the dietary stress, it is possible that the protective potential 
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of a pharmacologic Nrf2 inducer such as WA is inadequate. Comparison of multiple genotypes 
is particularly challenging since some genetic alterations (particularly with Nrf2 signaling) may 
allow for faster or slower progression within the NAFLD disease spectrum. Further experiments 
are required to determine whether pharamacologic activation of Nrf2 signaling can be protective 
against MCD diet induced NAFLD particularly within the earlier (<1 week) and later (> 4 weeks) 






5.0  CONCLUSIONS 
5.1 GENERAL SUMMARY AND CONCLUSIONS 
Overall, studies conducted for this dissertation revealed that WA is a potent inducer of 
Nrf2 signaling. As highlighted in chapter 2, WA profoundly protected mice against APAP-
induced hepatotoxicity in an Nrf2-dependent manner. The cytoprotection rendered by Nrf2 
target genes was observed in multiple organs suggesting the systemic nature of Nrf2 induction 
by WA. In chapter 3, important mechanistic details of WA-mediated Nrf2 induction was 
unraveled where it was shown that WA induced Nrf2 signaling independent of Keap1 using in 
vitro models. This response was also shown to be dependent on PI3K signaling suggesting that 
WA likely modulated the PI3K/GSK3/β-TrCP axis to activate Nrf2 signaling. Furthermore, the 
potency of WA (CD=80 nM) was shown to be much higher than that of sulforaphane (CD=1.5 
μM) in MCF10A cells in inducing NQO1 transcription.  
Although Nrf2 signaling was shown to be directly modulated by WA in providing 
protection against APAP hepatotoxicity, the same was not observed in MCD diet-induced 
steatohepatitis, a different model of hepatotoxicity. While it has been extensively documented 
that enhanced Nrf2 signaling protected against both APAP as well as MCD diet-induced liver 
damage, reports on pharmacologic Nrf2 induction mitigating MCD diet-derived steatohepatitis is 
currently absent. Additionally, in a subacute model of hepatotoxicity where a large number of 
mechanistic alterations are caused as a result of repeated exposure to the stressor, a 
differential outcome is expected compared to an acute model of toxicity such as a 6 hour 
exposure to APAP. The notion that the protective aspects of Nrf2 are observed in specific 
 116 
stages of a given disease has been highlighted by others (discussed in the next section) and 
needs to be incorporated into future chemoprevention studies. Provided that Nrf2 induction by 
pharmacologic means essentially utilizes stimulation of the pathway with low levels of 
electrophilic stress, sometimes using pharmacologic interventions could potentially not result in 
protective phenotypes, especially if the cell or organism is already under irreversible amounts of 
stress, an observed with the MCD diet-induced steatohepatitis study.  
Our findings here have important implications in the advancement of WS and WA into 
population-based clinical trials. Although WA was the primary focus of our studies, some 
preliminary experiments were carried out with WS as well with three different types of 
withanolides to determine how each component induced Nrf2 signaling (Figure 5.1). Graded 
doses of WS root extract (standardized to WA) was used to treat MCF10A cells for 20 hours 
after which RNA was isolated to determine relative mRNA expression of NQO1. WS root extract 
concentration was predetermined during its preparation by standardization to the pure 
compound WA [140]. Our results suggested that 0.3 μM WS root extract resulted in ~3-fold 
induction of NQO1 transcripts (Figure 5.1A). In comparison, 0.7 μM WA resulted in the highest 
induction of NQO1 transcripts (~8-fold) in MCF10A cells (Figure 3.2B). We also compared 
NQO1 transcript induction following treatment of wild-type and Nrf2-knockout MEF with multiple 
withanolides typically present in the WS root extract. Results indicated that 1 μM WA resulted in 
the highest induction of NQO1 transcripts in wild-type MEFs as compared to the same 
concentration of withanolide A and withanone (Figure 5.1B). Interestingly, withanone showed 
~2-fold induction of NQO1 transcripts in wild-type MEF suggesting that while WA is the most 
efficacious in inducing Nrf2 signaling, other withanolides could also potentially activate this 
pathway. The Nrf2-dependence of the response was apparent as all of the withanolides were 
relatively unresponsive to inducing NQO1 expression in Nrf2 knockout MEFs. One caveat in this 
experiment however, is that different withanolides could potentially have different pharmacologic 
profiles and therefore can induce Nrf2 under varied conditions. Thus, at 1 μM concentration, WA 
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may be the most efficacious in inducing Nrf2 but at another concentration, the outcome may be 
different. Hence, it is important to establish the pharmacodynamics and pharmacokinetics for 
each withanolide separately. These studies warrant further exploration and will allow WS to be 
comprehensively characterized as an Nrf2 inducer as well.  
Overall, we have identified WA as a modulator of Nrf2 signaling, a major mechanism by 
which cells respond to exogenous and endogenous stress. Furthermore, Nrf2 is a validated 
target for chemoprevention as well as for prevention of various other forms of toxicity. We have 
incorporated models of hepatotoxicity to show that Nrf2 modulation by WA results in significant 
health outcomes where WA enables cells and organisms to enhance their cytoprotective 
capacity to defend themselves against injury. Although direct models of carcinogenesis were not 
used during our experiments, it is predictable that the anti-carcinogenic effects of WA and WS 
that have been observed by others, are in fact driven substantially by Nrf2 signaling, given the 
irreplaceable role of Nrf2 in cancer. Further experimentation incorporating Nrf2-deficient mice in 
animal carcinogenesis models where WA has effectively prevented tumor incidence may help 







Figure 5-1. Cytoprotective actions of WS root extract and withanolides. 
A) Induction of NQO1 mRNA after MCF10A cells were treated with graded doses of Withania 
somnifera root extract. The root extract was kindly provided by Dr. Adam Marcus. B) Induction 
of NQO1 mRNA after wild-type and Nrf2 knockout MEFs were treated with either DMSO control 
or 1 μM WA, withanolide A (WLA) or Withanone (WN). Withanolides were provided by Dr. 
Shivendra Singh. Values are mean ± SEM (p<0.05).  
5.2 EXTENDING PRE-CLINICAL EFFORTS TO HUMAN CHEMOPREVENTION TRIALS 
USING WS 
5.2.1 Past human clinical trials using WS 
So far, no clinical trials in human populations have been carried out with WS or WA with 
cancer or cancer biomarkers as end points. However, WS has been tested in a few clinical trials 
against other disorders and conditions. While many of these studies suffer from major 
drawbacks, including but not limited to small sample sizes, use of mixtures of compounds and 
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utilizing only older individuals as study participants, there are some important lessons learned 
for future clinical and translational work involving WS and WA.  
A few studies have assessed the effects of WS on immunologic endpoints such as 
lymphocyte activation and NK cell activity. In a smaller study carried out by Mikolai et al., [179] 5 
healthy study participants were administered 6 ml of WRE with cow’s milk, twice daily for 5 days 
[179]. Significant increases in expression of CD4+ and CD3+ T cells as well as CD56+ NK cells 
were observed after 96 hours. Bhat et al. [180] performed a study with a larger number of 
participants, but also used a concoction of several different herbs. Volunteers consumed three 
cups of either regular tea or natural care tea that included 4 herbs including WS. The results 
showed that natural care tea consumption enhanced NK cell activity. Second-generation 
antipsychotic drugs are associated with higher incidence of metabolic syndrome. Clinically 
diagnosed schizophrenia patients who had received antipsychotic medications for 6 months or 
more received either a capsule with 400 mg of WS extract (n=15), three times daily, for 1 month 
[312]. Results after one month showed significant reduction in serum triglycerides and fasting 
blood glucose levels in the WS extract- treated group compared to the placebo.  
Biswal et al. [313] estimated the potential of WS to reduce chemotherapy-induced 
fatigue and quality of life in a prospective, open-label, non-randomized comparative clinical trial. 
Patients in the control arm experienced significantly higher estimated marginal means of fatigue 
scores compared with the treatment arm that received 2 g of WS root extract every 8 hours 
throughout the course of chemotherapy. Additionally, a survival analysis showed that patients in 
the WS treatment group had a better 24-month survival rate of 76% as compared to the control, 
which was 56%. Although this finding was not statistically significant, it could be attributed to the 
high heterogeneity in breast cancer types. Also, the possible drug-drug interaction between 
chemotherapy agents and WS was not evaluated, making it particularly difficult to determine 
whether the observed effects are direct or not. In an interesting translational study, the role of 
WA in cancer epigenetics was evaluated. First it was shown that DNA methyltransferases 
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(DNMT) are over expressed in human invasive ductal tissue isolated from cancer patients [314]. 
The researchers subsequently showed that in MCF7 and MDA-MB-231 breast cancer cells WA 
treatment suppressed transcription of DNMT. These results indicated that WA is a modifier of 
the epigenetic response, a finding that warrants further exploration. 
5.2.2 Utilizing WS as a nutraceutical to prevent cancer: Challenges and lessons for the 
future 
Promoting WS towards chemoprevention in humans requires overcoming several 
barriers. These are summarized in Table 5.1. From an agricultural perspective, bulk 
manufacturing of WS is associated with several concerns. Firstly, the plant thrives under 
specific environmental conditions and requires time and effort to grow conventionally. However, 
new technologies such as in vitro hairy root cultures of Ashwagandha that may assist in this 
matter have emerged [315]. Secondly, research has also identified that there is large variability 
in amount of alkaloids and withanolides produced by each plant, and in different parts of the 
plant which can directly interfere with production of preparation with uniform bioactivity 
[133;316]. Thus, strict quantification and standardization methods should be utilized to pre-
determine concentrations of alkaloids and withanolides in each preparation. Thirdly, even 
though the WS plant is resistant to pest attacks, some mite and insect infestations have been 
noticed. Ensuring that fertilizers and pesticides are not overused, especially given the fact that 
plant roots are used, is vital. In addition, utilizing novel methods to produce WS and its 
withanolides can help meet the increasing global demand in a sustainable way and will facilitate 
determination of its chemopreventive potential.  
Design of chemoprevention trials should incorporate insights from the traditional uses of 
WS as well. Its common use as an adaptogen that promotes homeostasis and as an energy 
enhancer may suggest potentially useful modes of action of the drug. Research work cited here 
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are dedicated to understand these biological pathways modulated by WS and its withanolides. 
Pre-clinical studies, performed either in cell culture or in animal models that mimic appropriately 
relevant conditions of populations, need to be utilized for this purpose. Evaluating the 
chemopreventive efficacy of not only WA but also extracts of WS in a broader range of animal 
carcinogenesis models would bolster the potential role of WS to prevent cancer (Figure 5.2). 
Data gathered from such studies would be beneficial in 1) understanding the 
pharmacodynamics and pharmacokinetics of Ashwagandha 2) modifying structural moieties of 
withanolides to assess the role of chemical structures in the mechanism of action 3) identifying 
molecular events involved in WS-mediated effects to specifically target signaling pathways that 
are validated for cancer chemoprevention 4) determining whether co-administration with other 
agents (compounds used in traditional medicine to complement Ashwagandha or agents that 
are currently used in Western cancer chemoprevention trials) could potentially render higher 















Table 5-1. Proposed actions for developing WS as a chemopreventive agent in human 
populations 
 
Phase Action items 
 
Agricultural 
- Bulk production 
- Pest control 
- Contamination 
 
- Identifying optimal chemotype variants of WS 
- Promoting minimal usage of fertilizer and pesticides 
- Utilizing fields that are low in heavy metal contamination 
to grow WS 




- Extraction  
- Quantification 
 
- Incorporating efficient methods of extraction  






- Side effects 
 
 
- Screening for potency in cell and animal models using 
activation of biological pathways validated in 
chemoprevention 




- Identify population 
- Administer 
- Monitor  
 
 
- Identifying suitable at risk populations for cancer, 
preferably within regions of the world were WS is used 
in traditional medicine 
- Treating with WS as per findings from pre-clinical 
studies 
- Observing for 1) biomarkers of WA-mediated pathway 
activation 2) withanolides in blood or urine 
- Long-term monitoring for modulation of biomarkers or 




Inasmuch as there many naturally-occurring dietary agents currently under investigation 
for their potential to prevent or treat cancer, it becomes important to prioritize these compounds 
based on efficacy and safety. Although many of these agents may target different biological 
pathways and may have inherently different pharmacological profiles, they need to be compared 
in common models, especially in vivo ones. This has not been done to date. Nonetheless, the 
evidence that WS can be beneficial against a wide array of diseases highlighted in the previous 
section serves as a testimony to the need develop WS as a chemopreventive agent against 
cancer in humans. Invariably, considerations for dosage, time course as well as other 
pharmacological parameters of the agent need to be accounted for. Especially for 
chemopreventive studies, a non-toxic dose of WS will need to be administered over a prolonged 
period of time to determine whether it can prevent, block or reverse aspects of the carcinogenic 
process. Therefore, determining a safe dosage window, developing a precise administration 
regimen as well as understanding the bioavailability in preclinical studies is a prerequisite of 
promoting WS for clinical work as a chemopreventive agent. Being able to track the response to 
a chemopreventive agent in a non-invasive manner to the study participants is pivotal, 
particularly in long-term trials. Determining if WS metabolites can be detected in human blood, 
urine or saliva would be a useful tool to have [317]. Clinical development pathways with foods 
like sulforaphane-rich broccoli provide reasonable starting points for novel plant-derived agents 
such as WS [318]. With plant extracts, it is imperative that careful characterization of 
components in the extract is performed prior to starting the intervention regimen. Given the 
prolific evidence that WA performs well in preventing DMBA-induced oral carcinogenesis, it 
maybe a worthwhile consideration to first test WS in head and neck cancer prevention human 
trials. The fact that head and neck cancers are highly prevalent in South Asian nations, 
including India [319], where coincidentally WS is abundantly used in traditional medicine, 
presents an important and appropriate target population to fulfill a public health need.  
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Figure 5-2. Proposed scheme for designing studies with WS and WA that can 
successfully advance to human cancer clinical trials. 
With a rapidly expanding elderly population and relatively underdeveloped cancer 
research, treatment and care programs, less developed nations are likely to be the hardest hit 
by the cancer tsunami in the next few decades. Therefore, prevention of cancer, specifically by 
means of food or other dietary agents is likely the most cost-effective and sustainable method of 
dealing with this epidemic. The identification and characterization of dietary agents with 
chemopreventive potential are pivotal steps in this process. Traditional medicine systems such 
as Ayurveda have deep roots in many of these underdeveloped communities and present a 
great opportunity for battling the global burden of cancer from the stand point of primary 
prevention. Seeking out and researching plant-based agents that have a long standing history in 
traditional medicine can possibly be more effective than developing cancer treatment drugs from 
scratch, in terms of cost, convenience of administration and cultural acceptability. Given the 
central role of WS in Ayurveda and its promising actions in the realm of modern cancer 
research, it has potential to move forward as a cancer chemopreventive nutraceutical.  
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Although the promise of utilizing WS and potentially also WA in human chemoprevention trials, 
attention needs to be paid to how past clinical trials with plant-based agents were carried out as 
well as their results. While the two clinical trials using tamoxifen and retinol (discussed in 
Chapter 1, section 1.1.5)  showed overall positive results, participants of both of them had 
significant side effects [320]. There are also other reasons as to why chemoprevention has not 
been as successful in human trials. Firstly, using populations of individuals who are already at a 
high risk for development of disease (for example, current smokers) has had extremely negative 
consequences on the progress of the field of chemoprevention. At a time when scientists were 
becoming excited about the potential of β-carotene as a chemopreventive compound, testing its 
properties against lung cancer prevention in current smokers in fact suggested that the 
compound enhanced the chance of developing lung tumors in these individuals [321],[322]. 
Secondary follow-up done with the Physician’s Health Study showed that β-carotene did not 
raise risk of lung cancer in former or never smokers. Secondly, the dose and duration of the 
treatment may also result in differential results. In the trials that showed negative effects of β-
carotene, the dose used was 20 mg/ day, daily for 5-8 years as opposed to the dose used in the 
Physicians Health Study analysis that utilized 50 mg/ day, every other day, for 12 years. The 
inability to establish the exact conditions for human clinical trials in pre-clinical studies and 
utilizing populations that are already at too high a risk for disease development can result in the 
unfortunate conclusion of many optimistic chemopreventive agents.  
Another potentially important consideration, particularly with regard to utilizing 
pharmacologic inducers of Nrf2 signaling in human chemopreventive trials is to consider the 
exact role Nrf2 plays in carcinogenesis. Of course the protective role of enhanced Nrf2 signaling 
against carcinogenesis is irrefutable and has been discussed in detail throughout this 
dissertation, both in genetic and pharmacologic models. However, emerging evidence suggests 
that several other factors may need to be taken in to consideration. In a urethane-induced 
model of lung carcinogenesis, it was observed that while Nrf2 knockout mice showed increased 
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number of tumor foci by 8 weeks, in the same mice the number of tumors with malignant 
characteristics reduced by 16 weeks [323]. Interestingly, the wild-type tumors were associated 
with Kras mutations which was not observed in the Nrf2-knockout tumors. This was suggestive 
of the notion that Nrf2 prevented initiation of tumors but accelerated progression possibly via 
modulating Kras. To corroborate the data from the urethane study, in a model of skin 
carcinogenesis, it was revealed that transgenic mice that constitutively expressed Nrf2 (K5cre-
caNrf2) were mildly protected against DMBA/TPA induced skin cancer [324]. However, in a non-
chemical carcinogen model where Nrf2 overexpressing transgenic mice were mated with K14-
HPV8 mice (the latter mice develop spontaneous skin papillomas), it was observed that tumor 
development was accelerated with the activation of Nrf2. Furthermore, Nrf2 activation was also 
associated with heightened survival of premalignant cells. The authors of this study concluded 
that the protective role of Nrf2 is therefore potentially dependent on the model. Collectively, 
these studies indicate that the role of Nrf2 in carcinogenesis is likely to be dependent on the 
exact stage of carcinogenesis a given cell is at (for eg. tumor initiation vs. promotion vs. 
progression). Incidentally, the Nrf2 status is a likely contributor to the carcinogenic potential of a 
given cell given the complex nature of the crosstalk between Nrf2 and other pro-oncogenic 
molecules, such as Kras and Notch. Hence, the field of Nrf2-mediated chemoprevention needs 
a better understanding of how other molecular signaling networks may contribute to the 
chemopreventive capacity of Nrf2. During late stage malignancy, where the normal machinery 
of a cell is heavily altered, the cytoprotective nature of Nrf2 itself could be exploited by cancer 
cells for their survival. Thus, identifying how Nrf2 drives this “tipping point” between health and 
disease can potentially define the manner in which Nrf2 inducers are utilized for disease 
prevention. 
 While the pro-tumorigenic potential of Nrf2 in late stage carcinogenesis has only been 
described thus far in genetic models of altered Nrf2 signaling, pharmacologic induction of Nrf2 
too is not always associated with protective phenotypes.  When 12.5 or 50 mg/kg CDDO-Im or 
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CDDO-Me was administered to A/J mice (a model of lung carcinogenesis) the number of lung 
tumors were significantly reduced compared to mice that were administered 400-1200 mg/kg 
dimethyl fumerate, where in fact the average number of tumors was increased compared to 
vehicle controls [325]. Given that two different Nrf2 inducers can have differential effects on 
tumorigenesis, it becomes imperative to test each inducer in pre-clinical models that best mimic 
human carcinogenesis prior to utilizing them in chemoprevention clinical trials. The effect of 
long-term administration of Nrf2 inducers to healthy individuals within the realm of cancer risk is 
currently unknown. One of the challenges of accurately determining this outcome is the absence 
of reliable biomarkers of early stage carcinogenesis. Urinary metabolites of air pollutants such 
as benzene and acrolein were shown to be significantly reduced in individuals who consumed a 
broccoli sprout-derived beverage (600 μmol glucoraphanin and 40 μmol sulforaphane, daily for 
12 weeks) [326]. This type of quantification of intermediary metabolites can likely provide 
important insight as to how a given Nrf2 inducer can perform in long term chemoprevention 
trials. However, prospective trials need to be set up in order to unravel the exact role Nrf2 plays 
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